Zeo ScientifiX (ZEOX) 10-K 29 Jan 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Oct. 31, 2023	Jan. 28, 2024	Apr. 28, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Oct. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--10-31
Entity File Number	000-55008
Entity Registrant Name	ORGANICELL REGENERATIVE MEDICINE, INC
Entity Central Index Key	0001557376
Entity Tax Identification Number	47-4180540
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3321 College Avenue
Entity Address, Address Line Two	Suite 246
Entity Address, City or Town	Davie
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33314
City Area Code	(888)
Local Phone Number	963-7881
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 7,197,268
Entity Common Stock, Shares Outstanding		6,125,482
Documents Incorporated by Reference [Text Block]	None
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Weinberg & Company P.A.
Auditor Firm ID	572
Auditor Location	Los Angeles, CA

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Current Assets
Cash	$ 1,756,202	$ 3,753,097
Accounts receivable, net of allowance for bad debts	18,212	55,110
Receivables from related parties		128,939
Other receivables	11,378	7,433
Prepaid expenses	106,184	173,152
Inventories	310,183	248,510
Total Current Assets	2,202,159	4,366,241
Property and equipment, net	572,726	1,683,516
Other assets – right of use		110,995
Security deposits	7,315	39,936
TOTAL ASSETS	2,782,200	6,200,688
Current Liabilities
Accounts payable and accrued expenses	2,611,969	2,378,531
Advances payable to former officer	220,897	220,897
Finance lease obligations	23,107	143,748
Operating lease obligations		82,407
Promissory note, net of debt discount		563,111
Convertible promissory note, net of debt discount	656,853
Commitment Fee Shortfall Obligation		174,462
Commitment to repurchase shares in connection with settlement of litigation		500,000
Deferred revenue	497,259
Total Current Liabilities	4,010,085	4,063,156
Long term finance lease obligations	13,134	220,340
Long term operating lease obligations		28,588
Total Liabilities	4,023,219	4,312,084
Stockholders’ (Deficit) Equity
Common stock, $0.001 par value, 2,500,000,000 shares authorized; 7,283,483 and 7,395,632 shares issued and outstanding, respectively	7,284	7,396
Additional paid-in capital	56,259,711	52,402,514
Accumulated deficit	(57,508,014)	(50,521,306)
Total Stockholders’ (Deficit) Equity	(1,241,019)	1,888,604
TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ (DEFICIT) EQUITY	2,782,200	6,200,688
Series C Preferred Stock [Member]
Shares Subject To Possible Redemption
Preferred stock value

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Oct. 31, 2023	Oct. 31, 2022
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	7,283,483	7,395,632
Common stock, shares outstanding	7,283,483	7,395,632
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100	100
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Income Statement [Abstract]
Revenues (includes sales to related parties of approximately $115,440 and $329,600, respectively)	$ 4,558,278	$ 6,491,008
Cost of revenues	507,629	753,534
Gross profit	4,050,649	5,737,474
General and administrative expenses (including write-off of $142,405 of officers advances in 2023)	10,817,627	14,580,434
Loss from operations	(6,766,978)	(8,842,960)
Other income (expense)
Interest expense	(431,424)	(398,260)
Change in Commitment Fee Shortfall Obligation	(18,917)	(30,692)
Impairment of non-marketable securities in a related entity	(100,000)
Gain on sale of assets	340,611
Gain from write-off of liabilities attributable to discontinued operations		125,851
Other	(10,000)	249,504
Net loss	$ (6,986,708)	$ (8,896,557)
Net loss per common share - basic	$ (0.99)	$ (1.56)
Net loss per common share - diluted	$ (0.99)	$ (1.56)
Weighted average number of common shares outstanding - basic	7,028,638	5,688,230
Weighted average number of common shares outstanding - diluted	7,028,638	5,688,230

CONSOLIDATED STATEMENTS OF OP_2

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Income Statement [Abstract]
Revenues from related parties	$ 115,440	$ 329,600

CONSOLIDATED CHANGES TO STOCKHO

CONSOLIDATED CHANGES TO STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Oct. 31, 2021	$ 5,662	$ 38,953,494	$ (41,624,749)	$ (2,665,593)
Beginning balance, shares at Oct. 31, 2021	5,661,805
Sale of common stock	$ 1,413	7,288,587		7,290,000
Sale of common stock, Shares	1,412,500
Stock-based compensation	$ 263	3,916,327		3,916,590
Stock based compensation, Shares	263,250
Shares issued in Restructuring
Capital contributed by Executive		250,000		250,000
Warrants issued to executives as payment for outstanding compensation		649,740		649,740
Executive forgiveness of employment obligations in connection with Restructuring		1,526,893		1,526,893
Commitment to repurchase shares in connection with settlement of litigation		(500,000)		(500,000)
Common stock issued as commitment fee for Promissory Note	$ 23	156,208		156,231
Common stock issued as commitment fee for Promissory Note, Shares	23,077
Exchange of accounts payable for stock	$ 25	117,475		117,500
Exchange of accounts payable for stock, shares	25,000
Stock issued in settlement of litigation	$ 10	43,790		43,800
Stock issued in settlement of litigation, Shares	10,000
Net loss			(8,896,557)	(8,896,557)
Ending balance, value at Oct. 31, 2022	$ 7,396	52,402,514	(50,521,306)	1,888,604
Ending balance, shares at Oct. 31, 2022	7,395,632
Sale of common stock	$ 22	99,978		100,000
Sale of common stock, Shares	22,282
Stock-based compensation	$ 26	3,208,750		3,208,776
Stock based compensation, Shares	25,969
Issuance of Common stock and Warrants as commitment fee for SPA 23 Note	$ 75	282,425		282,500
Issuance of Common stock and Warrants as commitment fee for SPA 23 Note, shares	75,000
Discount on warrants issued with convertible debt		72,430		72,430
Stock issued in satisfaction of Commitment Fee Shortfall Obligation	$ 59	193,320		193,379
Stock issued in satisfaction of Commitment Fee Shortfall Obligation, shares	58,600
Cancellation of shares repurchased in connection with litigation	$ (124)	124
Cancellation of shares repurchased in connection with litigation, shares	(124,000)
Return of former executive’s shares and warrants	$ (170)	170
Return of former executive's shares and warrants, shares	(170,000)
Net loss			(6,986,708)	(6,986,708)
Ending balance, value at Oct. 31, 2023	$ 7,284	$ 56,259,711	$ (57,508,014)	$ (1,241,019)
Ending balance, shares at Oct. 31, 2023	7,283,483

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,986,708)	$ (8,896,557)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	486,354	332,508
Amortization of OID and commitment fee discount – Promissory Note	349,272	323,111
Change in Commitment Fee Shortfall Obligation	18,917	30,692
Gain from sale of assets	(340,611)
Gain from write-off of liabilities attributable to discontinued operations		(125,851)
Gain from write-offs and settlements of accounts payable and notes payable		(249,504)
Write-off of non-marketable securities	100,000
Write-off of receivables from officers and other receivable	142,405
Write-off of fixed assets	36,219
Reserve for bad debt		27,500
Write-off of inventory		37,455
Stock issued in settlement of litigation		43,800
Stock-based compensation	3,208,776	3,916,590
Changes in operating assets and liabilities:
Accounts receivable, net of allowance for bad debts	36,898	17,148
Receivables from related party		(128,939)
Other receivable	(17,411)	(7,433)
Prepaid expenses	66,968	(103,505)
Inventories	(61,673)	(51,138)
Accounts payable and accrued expenses	233,439	1,035,609
Accrued liabilities to management		657,003
Security deposits	32,621	(14,754)
Deferred revenue	497,259	(9,575)
Net cash used in operating activities	(2,197,275)	(3,165,840)
CASH FLOWS FROM INVESTING
Purchase of fixed assets	(25,391)	(824,743)
Proceeds from sale of assets	740,957
Investment in non-marketable equity securities	(100,000)
Net cash provided by (used in) investing activities	615,566	(824,743)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable	1,229,400	540,000
Shares repurchased in connection with litigation	(500,000)
Capital contributed by former executive		250,000
Payments on finance leases	(114,586)	(59,930)
Repayments of notes payable	(1,130,000)	(364,960)
Proceeds from sale of common stock	100,000	7,270,000
Net cash (used in) provided by financing activities	(415,186)	7,635,110
Increase (decrease) in cash	(1,996,895)	3,644,527
Cash at beginning of period	3,753,097	108,570
Cash at end of period	1,756,202	3,753,097
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for taxes
Cash paid for interest	67,145	78,625
NON-CASH INVESTING AND FINANCING TRANSACTIONS:
Executive forgiveness of employment obligations in connection with Restructuring		1,526,893
Warrants issued to executives as payment for outstanding compensation		649,740
Warrants issued in connection with convertible notes	72,430
Finance lease assigned to buyer in connection with asset sale	213,261
Stock issued in exchange for accounts payable		117,500
OID discount on proceeds received from Promissory Note	10,600	60,000
Stock purchased from payments due on accounts payable		20,000
Common stock issued as commitment fee for Promissory Note	282,500	156,231
Commitment Fee Shortfall Obligation		143,769
Commitment to repurchase shares in connection with settlement of litigation		500,000
Promissory note issued for past due Professional Fees		256,000
Purchase of fixed assets included in accounts payable		77,865
Common stock issued in satisfaction of Commitment Fee Shortfall Obligation	$ 193,379

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Organicell Regenerative Medicine, Inc. (“Organicell” or the “Company”) was incorporated on August 9, 2011 in the State of Nevada under the name Bespoke Tricycles Inc. (changed to Biotech Products Services and Research, Inc. during September 2015 and to Organicell Regenerative Medicine, Inc., effective June 20, 2018). The Company is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent (“RAAM Products”). Our RAAM Products and related services are principally used in the health care industry administered through doctors and clinics (“Providers”). On December 8, 2023, our board of directors and our stockholders holding a majority of the Company’s voting power, approved resolutions authorizing the Company to amend its Articles of Incorporation to change the name (“Name Change”) of the Company from Organicell Regenerative Medicine, Inc. to “Zeo ScientifiX, Inc.” Implementation and effectiveness of the Name Change will be subject to Organicell’s compliance with applicable regulatory requirements of the Securities and Exchange Commission and FINRA. For the years ended October 31, 2023 and 2022, the Company principally operated through General Surgical of Florida, Inc., a Florida corporation and wholly owned subsidiary, which was formed to sell the Company’s therapeutic products to Providers. The Company’s leading product, Zofin™ (also known as Organicell™ Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. The Company recently launched a service platform for its first autologous product called Patient Pure X™ (PPX™). PPX™ is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood. To date, revenues from PPX™ continue to be minimal. During the year ended October 31, 2023, the Company began to expand the use of its proprietary products in future formulations for a variety of topical use applications in the skin-care industry. On November 7, 2023, the Company filed a certificate of amendment to its Articles of Incorporation to affect a reverse split of our issued and outstanding common stock on a one-for-two-hundred basis. The reverse stock split was effective with FINRA on November 28, 2023 (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. As a result, on the effective date of the Reverse Split, the stated capital on the Company’s balance sheet attributable to the Company’s common stock was reduced proportionately based on the reverse stock split ratio of one-for-two hundred and the additional paid-in capital account was credited with the amount by which the stated capital was reduced. All per share amounts referenced herein are reflective of the Reverse Split.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Oct. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Concentrations of Risk Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $ 250,000 915,497 Major Customer During the year ended October 31, 2023, the Company sold products and services totaling approximately $ 1,301,000 28.5% 459,000 10.1% 460,000 10.1% During the fiscal year ended October 31, 2022, the Company sold a total of approximately $ 2,124,000 32.7% 1,413,700 21.8% 702,100 10.8% The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products. Major Supplier During the fiscal year ended October 31, 2023, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 113,100 86,900 57.0% 43.0% During the fiscal year ended October 31, 2022, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 145,000 130,000 53.0% 47.0% The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity. Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Accounts Receivable Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. Management determined that no 0 27,500 Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides a reserve for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At October 31, 2023 and 2022, the Company determined that no 37,455 Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 15 Non-marketable Securities Non-marketable securities consist of equity investments in privately held companies, which are classified as other assets on the consolidated balance sheets. These non-marketable equity securities do not have readily determinable fair values. Under the measurement alternative election, the Company accounts for these non-marketable securities at cost and adjusted for observable price changes in orderly transactions for the identical or similar investments of the same issuer or upon impairment and are not eligible for the net-asset-value practical expedient from fair value measurement. The measurement alternative election is reassessed each reporting period to determine whether the non-marketable securities continue to be eligible for this election. The Company periodically evaluates its non-marketable securities for impairment when events and circumstances indicate that the carrying amount of the investment may not be recovered. Impairment indicators may include, but are not limited to, a significant deterioration in earnings performance, credit rating, asset quality or business outlook or a significant adverse change in the regulatory, economic, or technological environment. Under current U.S. GAAP, equity investments without readily determinable fair values are reported at cost minus impairment. However, impairment losses are recognized only if they are considered other-than- temporary. The Company evaluated its investment in non-marketable securities at October 31, 2023, and determined such investment was impaired. Leasehold Improvements Leasehold improvements in excess of $1,000 that are made in connection with leases having a term of more than 12 months are capitalized by the Company and amortized over the shorter of the useful life of the asset or the remaining lease periods and renewals that are deemed to be reasonably certain at the date the leasehold improvements are purchased. Costs associated with leasehold improvements that do not exceed $1,000 are expensed as incurred. Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet. Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At October 31, 2023, the Company had 2,571,656 100,000 2,149,000 499,216 Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values. The Company periodically issues stock options and stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods. Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $ 922,700 791,300 Income Taxes The Company files a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the years ended October 31, 2023 and 2022 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the years ended October 31, 2023 and 2022. Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 7,283,483 Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. Operating Lease Obligations Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $ 15,000 Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2023 through the financial statement issuance date for subsequent event disclosure or recording.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern. The Company has had limited revenues since its inception. The Company incurred net losses of $ 6,986,708 2,197,275 57,508,014 1,241,019 1,807,926 United States Food and Drug Administration (“FDA”) regulations which were announced in November 2017 and which became effective in May 2021 require that the sale of products that fall under Section 351 of the Public Health Services Act pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products (“HCT/Ps”) can only be sold pursuant to an approved biologics license application (“BLA”). The Company has not obtained any opinion or ruling regarding the Company’s operations and whether the processing, sales and distribution of the products it currently produces would be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s. As a result of the above, the Company’s efforts to establish a stabilized source of sufficient revenues to cover operating costs has yet to be achieved and ultimately may prove to be unsuccessful unless (a) the Company’s ability to process, sell and distribute the products currently being produced or developed in the future are not restricted; and/or (b) additional sources of working capital through operations or debt and/or equity financings are realized. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products. The Company does not have any assets to pledge for the purpose of borrowing additional capital. In addition, the Company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers. The Company’s current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds. The Company anticipates that future sources of funding, if any, will therefore be costly and dilutive, if available at all. In view of the matters described in the preceding paragraphs, recoverability of the recorded asset amounts shown in the accompanying consolidated balance sheet assumes that (a) the Company is able to continue to produce products or obtain products under supply arrangements which are in compliance with current and future regulatory guidelines; (b) the Company will be able to establish a stabilized source of revenues, including efforts to expand sales internationally and the development of new product offerings and/or designations of products; (c) obligations to the Company’s creditors are not accelerated; (d) the Company’s operating expenses remain at current levels and/or the Company is successful in restructuring and/or deferring ongoing obligations; (e) the Company is able to continue its research and development activities, particularly in regards to remaining compliant with the FDA and ongoing safety and efficacy of its products; and/or (f) the Company obtains additional working capital to meet its contractual commitments and maintain the current level of Company operations through debt or equity sources. There is no assurance that the products we currently produce will not be subject to the FDA’s previously announced intended enforcement policies regarding HCT/P’s and/or the Company will be able to complete its revenue growth strategy. There is no assurance that the Company’s research and development activities will be successful or that the Company will be able to timely fund the required costs of those activities. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversely impacted. Furthermore, despite significant effort since July 2015, the Company has thus far been unsuccessful in achieving a stabilized source of revenues. If revenues do not increase and stabilize, if the Company’s ability to process, sell and/or distribute the products currently being produced or developed in the future are restricted, and/or if additional funds cannot otherwise be raised, the Company might be required to seek other alternatives which could include the sale of assets, closure of operations and/or protection under the U.S. bankruptcy laws. As of October 31, 2023, based on the factors described above, the Company concluded that there was substantial doubt about its ability to continue to operate as a going concern for the 12 months following the issuance of these financial statements.

RESTRUCTURING

RESTRUCTURING	12 Months Ended
	Oct. 31, 2023
Restructuring and Related Activities [Abstract]
RESTRUCTURING	NOTE 4 – RESTRUCTURING Effective July 13, 2022, the Company entered into (a) a binding letter of intent with Skycrest Holdings, LLC (“Skycrest”) and Greyt Ventures LLC (“Greyt,” and together with Skycrest, the “Skycrest/Greyt Group”) to invest $ 2,000,000 500,000 4.00 2,000,000 500,000 4.00 Pursuant to the binding letters of intent (the “LOIs”), the Company agreed to (a) make certain corporate governance changes as more fully described therein, including allowing the Investors to appoint new independent directors who will comprise a majority of the members of the Board; (b) enter into 36-month consulting agreements with each of Skycrest and Greyt (each, a “Consulting Agreement,” and collectively, the “Consulting Agreements”), pursuant to which (i) Skycrest and Greyt will provide certain advisory services to the Company as more fully set forth in the LOIs; and (ii) Skycrest and Greyt shall each be compensated for their services by the Company issuing to each of them ten year-warrants to purchase 750,000 4.00 Contemporaneously with entering into the respective LOIs, the Skycrest/Greyt Group and Beyond 100 each advanced Organicell $400,000 and $300,000, respectively (a total of $700,000) as good faith deposits against the $2,000,000 (a total of $4,000,000) purchase price for the Shares. On August 19, 2022 (“Closing”), the Company entered into stock purchase agreements (each, an “SPA” and collectively, the “SPAs”) with Skycrest Holdings, LLC (“Skycrest”), Greyt Ventures LLC (“Greyt”), Beyond 100 FZE (“Beyond 100”) and Smart Co. Holding Pte. Ltd. (“Smart Co,” and together with Skycrest, Greyt and Beyond 100, individually, an “Investor” and collectively, the “Investors”). Pursuant to the SPAs, the Company issued each Investor 250,000 shares of the Company’s common stock (“Shares”) at a price of $4.00 per Share ($1,000,000). In addition, under the SPAs with Skycrest and Greyt, the Company issued each of them 50 shares of newly designated Series C Non-Convertible Preferred Stock (the “Series C Preferred Shares”). The Series C Preferred Shares vote together with Shares of our common stock as a single class on all matters presented to a vote of stockholders, except as required by law and entitle Skycrest and Greyt to each exercise 25.5% of the total voting power of the Company. The SPAs with Skycrest and Greyt, also grant them the right, acting jointly, to designate a majority of the nominees to be elected to the Company’s board of directors at each annual meeting of the Company’s stockholders (the “Designation Right”). The Designation Right expires at such time as the Series C Preferred Shares are no longer outstanding. As a result of the issuance to Skycrest and Grey of the Series C Preferred Stock and the granting to them of the Designation Right, a “Change in Control” of the Company is deemed to have occurred. The SPA with Beyond 100 grants that Investor a right of first refusal for a period of 18 months from Closing with respect to any bona fide offer, or proposal received by the Company from or agreement in principal reached by the Company with a third party to enter into an exclusive arrangement providing for manufacturing, distributing, licensing, and commercializing any of its existing and/or future products and services to be manufactured, licensed and/or distributed by the Company or any of its subsidiaries in India. The SPAs also accord the Investors registration rights under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to which the Company has agreed to file a registration statement under the Securities Act with the Securities and Exchange Commission (the “SEC”) within 180 days of Closing and use its commercially reasonable efforts to cause such registration statement to be declared effective by the SEC within 60 days thereafter. The registration statement will cover the resale of the Shares pursuant to the SPAs, and in the case of Skycrest and Greyt, the Shares issued or issuable upon exercise of the Consulting Warrants. The SPAs also provide the Investors “piggy-back” registration rights with respect to their respective Shares. To date, the Investors have deferred any of the Company’s registration obligations pursuant to the SPA. Consulting Agreements At Closing, the Company also entered into 36-month consulting agreements with each of Skycrest and Greyt (each, a “Consulting Agreement,” and collectively, the “Consulting Agreements”), pursuant to which (a) Skycrest and Greyt will provide certain advisory services to the Company as more fully set forth therein; and (b) Skycrest and Greyt are being compensated for their services by the Company issuing to each of them at closing ten (10) year-warrants to purchase 750,000 Shares at an exercise price of $4.00 per Share (the “Consulting Agreement Warrants”), which Warrants are exercisable on a “cashless” basis (see Note 14).

INVENTORIES

INVENTORIES	12 Months Ended
	Oct. 31, 2023
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 5 – INVENTORIES Schedule of inventories October 31, October 31, Raw materials and supplies $ 153,868 $ 85,096 Finished goods 156,315 163,414 Total inventories $ 310,183 $ 248,510

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Oct. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 6 – PROPERTY AND EQUIPMENT Schedule of property and equipment October 31, October 31, Computer equipment $ - $ 26,881 Finance lease equipment 260,356 544,378 Manufacturing equipment 534,531 625,979 Leasehold improvements - 925,932 794,887 2,123,170 Less: accumulated depreciation and amortization (222,161 ) (439,654 ) Total property and equipment, net $ 572,726 $ 1,683,516 As described in Note 8, during the year ended October 31, 2021, the Company began the build-out of additional laboratory processing, product distribution and administrative office capacity at its Basalt Lab (as defined in Note 8). The Basalt Lab Lease location became operational during May 2022 and the depreciation of equipment and the amortization of the leasehold improvement costs at the Basalt Lab began during May 2022. Sale Of Basalt Lab Assets Effective, August 7, 2023, the Company sold the Basalt Lab (“Sale”) to a non-affiliated third-party purchaser (“Purchaser”). The transaction included the assignment of the Basalt Lab Lease and the lease for certain laboratory equipment and the sale of all leasehold improvements associated with the Basalt Lab and inventory. The purchase price paid by Purchaser was $ 1,252,000 752,000 500,000 213,261 340,611 11,100 Depreciation expense totaled $ 106,384 82,036 Amortization expense totaled $ 379,970 250,472

EQUITY IN NON-MARKETABLE SECURI

EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY	12 Months Ended
	Oct. 31, 2023
Equity In Non-marketable Securities Of Affiliated Entity
EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY	NOTE 7 – EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY Schedule of equity in non marketable securities affiliated entity October 31, October 31, Equity in non-marketable securities $ 100,000 - Reserve on carrying value of investment in non-marketable securities $ (100,000 ) - Equity in non-marketable securities $ - - During the year ended October 31, 2023, the Company invested $100,000 in cash (representing a 10% equity interest at the time of the investment) in the non-marketable equity securities of one privately held skin-care formulator (“Formulator”) in an effort to accelerate the Company’s development of expertise with respect to the skincare industry and the potential supply of the Company’s products in future topical formulations. The Company evaluated its ownership, contractual and other interests in this entity and determined the Company does not have a variable interest in this entity and therefore it is not required to be consolidated in the Company’s consolidated financial statements, as the Company is not the primary beneficiary and does not have the power to direct activities that most significantly impact the entities’ economic performance. The Company’s maximum loss exposure is limited to the carrying value of this investment. At the time of the investment, both Greyt Ventures, LLC and Skycrest Holdings, LLC, principal shareholders of the Company, each owned a 20% interest in the Formulator. In addition, Mr. Robert Smoley, a consultant and advisor to the Company is also the Chief Operating Officer of the Formulator. The Company’s, Greyt Ventures, LLC’s and Skycrest Holdings, LLC’s equity interests in the Formulator have since been reduced to 8.96%, 17.93% and 17.93%, respectively, as a result of additional sales of equity interests in the Formulator to outside parties. In addition, the Company’s CMO was granted an option to acquire up to 200,000 membership interests in the Formulator, of which 100,000 vested immediately and the remaining $100,000 will vest based on future sales of the Formulator attributed to the CMO. The option price is $20,000 for the 200,000 membership interests. As of October 31, 2023, the Company recorded a reserve against the carrying value of its investment of the Formulator of $100,000, based on the limited financial history of the Formulator to date to ascertain the fair value of the Formulator and the Company’s limited rights to control future dilution to the Company’s interests and the timing of available distributions, if any, of the Formulator. As such, at October 31, 2023, the carrying value of the Company’s investments in equity securities without readily determinable fair values totaled $0. Sales Representative Agreement During November 2023, the Company and the Formulator entered into a Sales Representative Agreement (“Sales Agreement”) in connection with the Company’s efforts to expand the use of its proprietary products for a variety of topical use applications. In connection with the Sales Agreement, the Company will receive commissions on the net sales value of Formulator products that are sold to pre-approved retailors, wholesale distributors, private label customers and direct to consumer customers which were introduced to the Formulator by the Company of 10%, 5%, 10% and 15%, respectively. Joint Supply Agreement The Company and the Formulator entered into an agreement whereby the Formulator has agreed to supply the Moisturizer that the Company is obligated to supply under the Amended Skincare Agreement (see Note 15).

LEASE OBLIGATIONS

LEASE OBLIGATIONS	12 Months Ended
	Oct. 31, 2023
Lease Obligations
LEASE OBLIGATIONS	NOTE 8 – LEASE OBLIGATIONS Finance Lease Obligations: During March 2019, the Company entered into a lease agreement for certain lab equipment in the amount of $ 239,595 4,513 1.00 4.5% 15 During October 2021, the Company entered into a second lease agreement in the amount of $ 304,873 5,478 1.00 3.0% 15 As described in Note 6, on August 7, 2023, certain equipment under the second lease agreement were assigned to the Purchaser resulting in the reduction of the Company’s remaining aggregate lease obligations by $ 213,261 As of October 31, 2023, finance lease obligations were $ 36,241 23,107 The weighted average remaining term of the Company’s Finance Leases as of October 31, 2023 was 7.4 Schedule of minimum lease payment to finance lease Year Ended October 31, Minimum 2024 $ 23,588 2025 5,536 2026 5,536 2027 2,768 2028 - Thereafter - Total undiscounted finance lease payments 37,428 Less: imputed interest (1,187 ) Present value of finance lease liabilities $ 36,241 Operating Lease: The Company’s previously leased corporate administrative offices from MariLuna, LLC. The lease term began July 1, 2020 and expired in July 2022 in connection with the Closing. The monthly rental rate of the lease was $ 3,500 117,659 4.5% 29,670 During March 2021, the Company entered into a lease agreement (“Basalt Lab Lease”) for an approximately 2,452 square foot commercial space located in Basalt, Colorado (the “Basalt Lab”). The term of the Basalt Lab Lease is for three years and may be renewed for an additional (3) three-year term provided the Company is not in default (“First Renewal Option”). Rental expense is $ 6,800 20,400 In connection with the execution of the Basalt Lab Lease, the Company recorded a ROU asset and corresponding operating lease obligation of $ 235,313 4.5% 110,955 49,750 20,400 61,246 76,351 0

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Oct. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS The Company’s corporate administrative offices were previously leased from MariLuna, LLC, a Florida limited liability company which is owned by a former executive under a lease agreement that expired June 30, 2023. The Company paid a security deposit of $ 5,000 3,500 0 31,500 Beginning October 1, 2020, the Company entered into a second lease agreement with Mariluna LLC for office space located in Aspen, CO. The initial term of the lease was for one year, expiring on September 30, 2021 and the lease was subsequently extended on a month to month basis. Under the terms of the lease, the Company was required to make monthly rental payments of $ 6,500 11,000 0 58,500 In connection with Mr. Bothwell’s executive employment agreements, the Company agreed to reimburse Rover Advanced Technologies, LLC (“Rover”), a company owned and controlled by Mr. Bothwell for office rent and other direct expenses (phone, internet, copier and direct administrative fees, etc.) totaling $ 0 36,352 For the year ended October 31, 2023, the Company sold a total of approximately $ 180,900 For the year ended October 31, 2022, the Company sold a total of approximately $ 702,100 101,715 At Closing, the Company and each of Albert Mitrani (a former executive of the Company) and Dr. Mari Mitrani (a former executive of the Company) agreed to forego unpaid salary amounts as of the date of the Closing in the amount of $ 430,200 563,455 Ian Bothwell waived all unpaid and accrued compensation in the amount of $1,043,478, in exchange for ten-year warrants to purchase 150,000 Shares at an exercise price of $4.00 per share, exercisable on a “cashless basis” and a cash payment of $50,000 at Closing. At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in the amount of $139,500 in exchange for ten-year warrants to purchase 15,750 Shares at an exercise price of $4.00 per share, exercisable on a “cashless basis.” During June 2022, Albert Mitrani, a former executive of the Company, made a capital contribution of $ 250,000 During the year ended October 31, 2023, the Company invested $ 100,000 the Company’s CMO was granted an option to acquire up to 200,000 membership interests in the Formulator, of which 100,000 vested immediately and the remaining $100,000 will vest based on future sales of the Formulator attributed to the CMO. The option price is $20,000 for the 200,000 membership interests (see Note 7). At October 31, 2023 and October 31, 2022, advances payable to an affiliate of a former executive were $ 220,897

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Oct. 31, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 10 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Schedule of account payable and accrued expenses October 31, October 31, Accrued payroll related liabilities $ 666,924 $ 666,780 Lab equipment and supplies payables 407,183 477,255 Clinical trial and research payables 675,284 312,711 Legal fees payables 478,810 328,121 Other professional fees payables 81,135 90,993 Accrued IRS penalty (Note 12) 86,319 83,684 Accrued commissions payable 101,627 39,675 Construction payables 9,317 5,474 Other payables and accrued expenses 105,370 373,838 Total Accounts Payable and Accrued Expenses $ 2,611,969 $ 2,378,531

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Oct. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 11 – NOTES PAYABLE Schedule of notes payable October 31, October 31, SPA 22 $ - $ 600,000 SPA 23 - - Convertible Promissory Notes 725,000 - Unamortized discount (68,147 ) (36,889 ) Total Notes Payable $ 656,853 $ 563,111 Unsecured Promissory Note For Professional Fees Owed On January 24, 2022, the Company reached an agreement with a professional firm in connection with unpaid legal services owing as of December 31, 2021 in the amount of $ 278,340 256,000 166,000 7,500 22,340 Promissory Note – SPA 22 On January 11, 2022, the Company entered into a Securities Purchase Agreement (“SPA 22”) with AJB Capital Investments, LLC (“Purchaser”) pursuant to which we sold a promissory note in the principal amount of $ 600,000 60,000 10% Pursuant to the terms of the SPA 22, the Company paid a commitment fee to the Purchaser in the amount of $ 123,000 15,385 8.00 33,231 7,692 4.32 Pursuant to the terms of the SPA 22, in the event that by the earlier of the first anniversary of repayment of the Promissory Note by the Company or the date that the Purchaser has sold all of the Commitment Fee Shares (“True-Up Date”), the Purchaser has not generated the amount of $ 300,000 Upon the closing, the Company recorded a discount of the Promissory Note in the amount of $ 260,000 60,000 123,000 77,000 100,000 33,231 66,769 For the year ended October 31, 2023 and 2022, $ 36,889 323,111 At February 10, 2023, the date that the Company received notice to repay the Commitment Fee Shortfall Obligation (see below) and October 31, 2022, the fair value of the Commitment Fee Shares was approximately $ 76,200 125,500 49,384 30,692 On February 10, 2023, the Company received a notice from the Purchaser that it had sold all of the Commitment Fee Shares and that the Commitment Fee Shortfall Obligation of $ 187,519 58,600 3.20 30,468 The total Commitment Fee Shortfall Obligation at October 31, 2023 and October 31, 2022 was $ 0 174,462 Promissory Note – SPA 23 On March 6, 2023, the Company entered into another Securities Purchase Agreement (“SPA 23”) with the Purchaser, pursuant to which we sold a promissory note in the principal amount of $ 530,000 15,000 504,400 12% Pursuant to the terms of the SPA 23, the Company paid a commitment fee to the Purchaser (“Commitment Fee”) in the form of 75,000 50,000 12.00 Upon the closing, the Company recorded a discount of the Promissory Note in the amount of $ 308,000 10,600 15,000 169,500 113,000 The discount is being amortized over the term of Note. For the year ended October 31, 2023, $ 308,000 Pursuant to the terms of the SPA 23, the Company granted certain piggyback registration rights under the Securities Act of 1933, as amended with respect to the Conversion Shares, the Warrant Shares and the Commitment Fee Shares. Convertible Promissory Notes During the period August 2023 through September 2023, the Company sold 2.9 Units (“Units”) to 4 investors in a private offering at a purchase price of $ 250,000 725,000 250,000 8% ” 7,813 0.001 20.00 Interest on the Convertible Promissory Notes are payable annually and together with the principal amount on the Maturity Date. The Convertible Promissory Notes may be prepaid by the Company, in whole, but not in part, at any time prior to the Maturity Date, subject to payment of a premium of 10%, provided that the Company gives the holders fifteen (15) business notice prior to prepayment, during which period, Investors may elect to convert the Notes and accrued but unpaid interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Note) for twenty consecutive (20) trading days ending on the date the Company gives the holders of the Convertible Promissory Notes notice of prepayment. Holders of the Convertible Promissory Notes will have the right, at any time during the period commencing on April 1, 2024 and ending on the earliest to occur of the Maturity Date, the date of a Prepayment or the date of an automatic conversion, to convert the Convertible Promissory Note in whole, but not in part, and accrued interest thereon into Shares at a conversion price equal to 80% of the average of the daily VWAP of the Shares (as defined in the Convertible Promissory Note) for twenty consecutive ( 20 6.00 In addition, the Convertible Promissory Notes and accrued but unpaid interest thereon will automatically convert into Shares in the event that prior to the Maturity Date, the Company consummates a “Qualified Financing” or a “Qualified Sale” (as defined in the Convertible Promissory Note) at a conversion price equal to 80% of the offering price of Shares sold in the Qualified Financing or 80% of the purchase price per Share to be received by stockholders following consummation of a Qualified Sale. The fair value of the Warrants issued was $ 80,469 The securities were offered and sold in a private offering exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemptions from registration afforded by Rule 506(b) of Regulation D under the Securities Act.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Oct. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 12 – INCOME TAXES The Company files a consolidated federal income tax return that includes all of its subsidiaries. For the years ended October 31, 2023 and 2022, the Company incurred operating losses, and therefore, there was not any current income tax expense amount recorded during those periods. The consolidated provision for income taxes for October 31, 2023 and 2022 consists of the following: Schedule of provision for income tax Year Ended Year Ended Current: Federal $ - $ - State - - Current Income Tax Expense (Benefit) $ - $ - Deferred: Federal $ (385,315 ) $ 4,405,121 State (349,335 ) 1,079,723 Deferred Income Tax Expense (Benefit) (734,650 ) 5,484,844 Change in Valuation Allowance 734,650 (5,484,844 ) Income tax provision $ - $ - Effective tax rates differ from the federal statutory rate of 21% Schedule of effective income tax rate October 31, October 31, Tax at federal statutory rate $ (1,467,209 ) $ (1,868,277 ) State taxes, net of federal benefit (349,335 ) (386,555 ) Permanent differences - 400,100 Stock-based compensation 834,282 6,609,802 Executive Forgiveness of employment obligations In connection with Restructuring - 480,109 Other 247,612 249,665 Total income tax expense (benefit) (734,650 ) 5,484,844 Change in valuation allowance 734,650 (5,484,844 ) Income tax provision $ - $ - The Company had a federal net operating loss carryover of $ 17,196,794 12,025,813 6,554,845 The tax effects of temporary differences and carry-forwards that give rise to deferred tax assets and liabilities for the Company were as follows: Schedule of deferred tax assets and liabilities October 31, October 31, Deferred Tax Assets: Stock based compensation $ 1,636,853 $ 798,239 Net operating loss carryforward-Federal 3,611,327 3,002,402 Net operating loss carryforward-State 617,525 396,530 Other - 1,477 Total deferred tax assets: 5,865,705 4,198,648 Deferred Tax Liabilities: Property and equipment 309,260 302,447 Total deferred tax liabilities: 309,260 302,447 Valuation Allowance (5,556,445 ) (3,896,201 ) Net deferred tax assets $ - $ - FASB ASC 740 requires a valuation allowance against deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. At October 31, 2023 and October 31, 2022, the net deferred tax asset was offset by a full valuation allowance. Pursuant to Code Sec. 382 of the Internal Revenue Code (“the Code”), the utilization of net operating loss carryforwards may be limited as a result of a cumulative change in stock ownership of more than 50% over a three-year period. The Company may be subject to such limitation. IRS Penalties The Company’s income tax returns for the periods since inception through the tax year ended October 31, 2015 were not filed with the Internal Revenue Service (“IRS”) until August 2017 (“Delinquent Filed Returns”). The Company’s income tax returns for the tax year ended October 31, 2016 were filed with the IRS during December 2017. In connection with the Delinquent Filed Returns, during the period September 2017 through October 2017, the Company received notices that it was being assessed approximately $ 90,000 20,000 86,319 83,684

CAPITAL STOCK

CAPITAL STOCK	12 Months Ended
	Oct. 31, 2023
Equity [Abstract]
CAPITAL STOCK	NOTE 13 – CAPITAL STOCK Preferred Stock The Company is authorized to issue 10,000,000 0.001 On August 17, 2022, the Company filed a Certificate of Designation for a newly created Series C Non-Convertible Preferred Stock consisting of 100 0.001 The Series C Preferred Shares vote together with shares of our common stock as a single class on all matters presented to a vote of stockholders, except as required by law. The Series C Preferred Shares are not convertible into common stock, do not have any dividend rights and do have a nominal liquidation preference. The Series C Preferred Shares also have certain protective provisions, such as requiring the vote of a majority of Series C Preferred Shares to change or amend their rights, powers, privileges, limitations and restrictions. Issued Shares In connection with the Closing (see Note 4), on August 19, 2022, the Company issued each of Skycrest and Greyt, 50 shares of the Series C Preferred Shares. The Series C Preferred Shares are automatically redeemed by the Company for nominal consideration at such time as the holder owns less than 50% of the Shares purchased pursuant to its SPA and Shares issued or issuable upon exercise of the Consulting Warrants or in the event the holder transfers or seeks to transfer the Series C Preferred Shares, other than by the laws of descent and distribution. Common Stock On November 7, 2023, the Company filed a certificate of amendment to its Articles of Incorporation to affect a reverse split of our issued and outstanding common stock on a one-for-two-hundred basis. The reverse stock split was effective with FINRA on November 28, 2023 (the “Reverse Split”). The par value of the Company’s common stock was unchanged at $0.001 per share after the Reverse Split. Issuances of Common Stock - Sales: In November 2021, the Company sold an aggregate of 40,000 10.00 400,000 In January 2022, the Company sold an aggregate of 3,333 6.00 20,000 In February 2022, the Company sold an aggregate of 41,667 6.00 250,000 During August 2022, in connection with the Closing, the Company sold an aggregate of 1,000,000 4.00 4,000,000 During August 2022 and September 2022, the Company sold an aggregate of 327,500 8.00 2,620,000 Issuances of Common Stock – Stock Based Compensation: In connection with agreements entered into with two former sales executives (“Sales Executives”), the Sales Executives were each granted 5,000 7.00 35,000 45,000 90,000 149,100 Effective March 29, 2021, the Company and Assure Immune L.L.C (“Consultant”) executed an amendment of the Consultant’s Agreement, whereby the Company issued to the Consultants 100,000 12.28 1,228,000 614,000 On August 9, 2021, the Company entered into an additional consulting agreement with a third party to provide consulting services in connection with the development of international research and development, sales and distribution and financing opportunities for a period of six months. The 10,000 185,400 18.60 92,700 During February 2021, the Company entered into a consulting agreement with a third party to provide consulting services for a one-year period. As consideration for agreeing to provide consulting services to the Company, the Company agreed to issue the consultant 2,500 shares of unregistered common stock upon completion of the three-month anniversary of the agreement. The shares issued were valued at $ 19.00 47,500 11,875 On June 4, 2021, the Company and a former employee agreed to amendment of the employee’s employment agreement. Under the terms of the amendment, the employee agreed to extend the term of the agreement through December 31, 2022 and the Company agreed to grant the employee 5,000 27.20 136,000 100,211 On December 27, 2021, the Company and an employee agreed to an amendment of the employee’s employment agreement. Under the terms of the amendment, the employee agreed to extend the term of the agreement through December 31, 2024 and the Company agreed to increase the employee’s annual salary from $ 180,000 210,000 5,000 5.80 29,000 22,958 On March 17, 2022, the Company entered into a consulting agreement with a third party to assist the Company with certain services associated with the implementation of the PPX™ service platform as well as other customary day to day activities as reasonably requested. The term of the agreement expired on September 30, 2022 (“Initial Term”). As consideration for agreeing to provide consulting services to the Company during the Initial Term, the Company agreed to issue the consultant 35,000 3.60 126,000 126,000 On June 9, 2022, the Company entered into a consulting agreement with a company affiliated with Mr. Sinnreich in connection with past and future consulting and advisory services to be provided to the Company. In connection with the consulting agreement, for the months of June 2022 and July 2022, the Company issued the consultant 8,500 10,000 3.80 2.70 59,300 On July 21, 2022, in connection with the Term Sheet, Mr. Sinnreich was issued 50,000 6.80 343,000 On July 21, 2022, in connection with the Term Sheet, during the first year of the Initial Term, Mr. Sinnreich was to be compensated by the issuance of 120,000 shares of Organicell’s common stock upon execution of the Term Sheet, which shall vest pro-rata in equal monthly installments of 10,000 shares each. The shares issued were valued at $6.80 per share, the closing price of the common stock of the Company on the effective date of the Term Sheet, totaling $823,200. On November 22, 2022, Mr. Sinnreich resigned from the Company. The Company amortized the costs associated with the issuance through the date of Mr. Sinnreich’s termination. For the year ended October 31, 2023 and 2022, a total of 7,233 and 33,534 shares, respectively, had vested and the Company recorded $ 49,618 228,353 On August 18, 2022, the Company entered into a consulting agreement with a third party to provide strategic marketing and digital marketing services for a minimum period of six months. As consideration for agreeing to provide consulting services to the Company, the Company will pay the consultant $15,000 per month and issued the consultant 12,500 shares of unregistered common stock valued at $4.82 per share, the closing price of the common stock of the Company on the effective date of the agreement. All of the shares granted vested immediately on the date of issuance. The Company will record $60,250 of stock-based compensation expense based on the grant date fair value of these shares during the term of the consulting agreement. The Company recorded $ 35,146 25,104 On December 1, 2022, the Company granted 750 6.00 4,500 On December 29, 2022, the Company agreed to issue 25,000 100,000 4.00 Equity Line Of Credit Commitment: During November 2021, the Company entered into an term sheet agreement with Tysadco Partners LLC, a Delaware limited company (“Tysadco”) whereby Tysadco agreed to provide the Company with a $1 0,000,000 35,000 10.00 15,000 201,000 On September 1, 2022, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Tysadco and a Registration Rights Agreement (the “Registration Rights Agreement”) with Tysadco. Pursuant to the Purchase Agreement, Tysadco committed to purchase, subject to certain restrictions and conditions, up to $10,000,000 worth of the Company’s common stock (the “Commitment”), over a period of 24 months from the effectiveness of the registration statement registering the resale of shares purchased by Tysadco pursuant to the Purchase Agreement (the “Registration Statement”). Pursuant to the terms of the Registration Rights Agreement, the Company was obligated to use its commercially reasonable efforts to file a registration statement with the Securities and Exchange Commission within thirty (30) days after the date of such agreement, to register the resale by Tysadco of the shares of common stock issuable under the Purchase Agreement. On September 2, 2022, the Company filed the required registration statement and on October 24, 2022, the Registration Statement was declared effective (“Registration”). The Purchase Agreement provides that at any time after the effective date of the Registration Statement, from time to time on any business day selected by the Company (the “Purchase Date”), the Company shall have the right, but not the obligation, to direct Tysadco to buy the lesser of $1,000,000 in common stock per sale or 500% of the daily average share value traded for the 10 days prior to the closing request date, at a purchase price of 80% of the of the two lowest individual daily VWAPs during the ten (10) trading days preceding the draw down or put notice (“Valuation Period”), with a minimum request of $25,000 (“Request”). The payment for the shares covered by each request notice will occur on the business day immediately following the Valuation Period. Pursuant to the Purchase Agreement, on December 2, 2022, the Company submitted a put request to Tysadco to purchase 22,282 registered shares at a purchase price of $4.49, for a total of $100,000 (“Put Request”). On December 5, 2022, Tysadco funded the Put Request and the Company issued 22,282 shares to Tysadco. The proceeds from the share sale were used for working capital and general corporate purposes. Due to overall market conditions, the Company determined that it would not seek to obtain additional financing through the ELOC Purchase Agreement and the ELOC Registration lapsed and is no longer effective and the Company can no longer receive additional fundings pursuant to the ELOC. Shares Issued - Promissory Note – SPA 22: As described in Note 11, in connection with the issuance of the Promissory Note on January 11, 2022, the Company issued the Purchaser’s 15,385 123,000 Shares Issued – SPA 23: As described in Note 11, in connection with the issuance of the Note on March 6, 2023, the Company issued the Purchaser’s 75,000 169,500 Shares Issued – Amendment of consulting agreement: On August 19, 2022 the Company and a consultant (“Consultant”) agreed to an amendment to the consulting agreement whereby the Consultant was issued 25,000 20,000 The shares issued were valued at $4.70 per share, the closing price of the common stock of the Company on the effective date of the settlement, totaling $117,500. The Company recorded a gain of $72,500 for the year ended October 31, 2022 in connection with the settlement, representing the difference in the fair value of the shares issued and the amount of obligations settled. Shares Issued – Settlement of Litigation: As described in Note 15, during April 2022 the Company settled a lawsuit whereby the Company paid LAE $ 45,000 10,000 43,800 Shares Repurchased – Settlement of Litigation: As described in Note 15, effective October 13, 2022, the Company settled a lawsuit by agreeing to repurchase 124,000 500,000 Management and Consultants Performance Stock Plan On April 25, 2020, the Company approved the adoption of the Management and Consultants Performance Stock Plan (“MCPP”) providing for the grant to current senior executive members of management and third-party consultants shares of common stock of the Company (“Shares”) based on the achievement of certain defined operational performance milestones (“Milestones”). Pursuant to the MCPP, a total of 1,712,500 shares have been issued. On October 29, 2021, the MCPP (but not Awards of unexchanged shares of our common stock) was terminated. In connection with the Closing, the Company and each of the grantees of awards authorized but not yet issued under the MCPP (“Awards”) agreed to waive and terminate their respective Awards. 2021 Plan and Share Exchange Agreement In September 2021, the Company adopted the 2021 Equity Incentive Plan (“2021 Plan”). The 2021 Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, and Performance Shares (an “Award”) to any person who is an employee or director of, or consultant to the Company. The maximum aggregate number of shares that may be issued pursuant to all Awards was 1,250,000 The 2021 Plan is administered by (a) the board of the directors of the Company; or (b) a committee designated by the board, which Committee shall be constituted in such a manner as to satisfy the applicable laws and to permit such grants and related transactions under the Plan to be exempt from Section 16(b) of the Exchange Act in accordance with Rule 16b-3. Once appointed, such committee shall continue to serve in its designated capacity until otherwise directed by the board. The board of directors may at any time amend, suspend, or terminate the Plan; provided, however, that no such amendment shall be made without the approval of the Company’s shareholders to the extent such approval is required by applicable laws. As of October 31, 2023, a total of 900,500 shares of our common stock (net of 181,500 shares of our common stock redeposited for future issuance) that have been awarded under the 2021 Plan remain issued and outstanding. As of October 31, 2022, a total of 417,000 Unvested Equity Instruments A summary of unvested equity instruments outstanding for the years ended October 31, 2023 and 2022 are presented below: Schedule of non vested share activity Number of Weighted- Outstanding at October 31, 2022 499,216 $ 11.35 Non-Vested Shares Granted - $ - Vested 169,983 $ 12.19 Expired/Forfeited 229,233 $ 10.35 Outstanding at October 31, 2023 100,000 $ 12.20 Number of Weighted- Outstanding at October 31, 2021 419,222 $ 12.34 Non-Vested Shares Granted 129,500 $ 6.86 Vested 49,506 $ 7.98 Expired/Forfeited - $ - Outstanding at October 31, 2022 499,216 $ 11.35 As of October 31, 2023, there was no unamortized compensation cost related to nonvested awards. As of October 31, 2022, the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which such costs are expected to be recognized was $855,030 and 7.0 months, respectively.

WARRANTS

WARRANTS	12 Months Ended
	Oct. 31, 2023
Warrants
WARRANTS	NOTE 14 – WARRANTS A summary of warrant activity for the years ended October 31, 2023 and 2022 are presented below: Schedule of warrant activity Number of Weighted- Remaining Aggregate Outstanding at October 31, 2022 2,149,000 $ 4.52 9.63 $ 2,440,110 Granted 737,656 $ 3.57 5.00 $ - Exercised - $ - - $ - Expired/Forfeited (315,000 ) $ 6.62 8.46 $ - Outstanding at October 31, 2023 2,571,656 $ 3.99 7.50 $ - Exercisable at October 31, 2023 1,959,365 $ 4.45 8.33 $ - Number of Weighted- Remaining Aggregate Outstanding at October 31, 2021 47,500 $ 6.11 6.90 $ 289,500 Granted 2,101,500 $ 4.48 10.0 $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding at October 31, 2022 2,149,000 $ 4.52 9.63 $ 2,440,110 Exercisable at October 31, 2022 1,940,242 $ 4.37 9.62 $ 2,403,058 On July 21, 2022, the Company issued Mr. Sinnreich (a former executive) a cashless warrant to purchase an aggregate of 200,000 6.80 2.91% 10 144% 0% 1,332,000 1,332,000 At Closing, the Company also entered into 36-month consulting agreements with each of Skycrest and Greyt (each, a “Consulting Agreement,” and collectively, the “Consulting Agreements”), pursuant to which (a) Skycrest and Greyt will provide certain advisory services to the Company as more fully set forth therein; and (b) Skycrest and Greyt are being compensated for their services by the Company issuing to each of them at closing ten (10) year-warrants to purchase 750,000 4.00 2.91% 10 144% 0% 2,940,000 2,940,000 1,960,000 408,333 At Closing, Ian Bothwell waived all unpaid and accrued compensation except for four unpaid base salary payments outstanding as of July 31, 2022, in exchange for ten-year warrants to purchase 150,000 4.00 2.91% 10 144% 0% 588,000 455,478 At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in exchange for ten-year warrants to purchase 15,750 4.00 2.91% 10 144% 0% 61,740 77,760 During August 2022, the Company entered into five separate consulting and employment agreements providing for the issuance of ten-year warrants to purchase an aggregate of 205,750 4.80 6.00 2.60% 3.05% 10 143% 0% 1,122,075 237,638 133,363 During September 2022, each of the five non-executive directors (other than the Chairman) were granted the right to be party to a Director’s Service Agreement. Pursuant to that agreement, non-employee directors will be compensated for their services by the annual issuance of warrants to acquire up to 5,000 8.80 3.69% 10 143% 0% 43,200 160,373 23,079 Effective August 1, 2022, the Company entered into a one-year consulting agreement with a third party to provide strategic advice, assistance with implementation of new business strategies and overall advice concerning the Company’s business goals and objectives. The consultant received compensation in the form of a warrant to acquire up to 5,000 6.60 2.60% 10 143% 0% 32,700 24,525 8,175 As described in Note 11, in connection with the issuance of the Note on March 6, 2023, the Company issued the Purchaser’s 50,000 12.00 3.98% 5 169% 0% 113,000 113,000 As described in Note 15, effective June 1, 2023, the Company issued Dr. Leider a warrant to purchase an aggregate of 285,000 2.40 3.7% 5 168% 0% 684,000 95,000 As described in Note 15, effective June 1, 2023, the Company issued Dr. Golub a warrant to purchase an aggregate of 250,000 2.40 3.7% 5 168% 0% 600,000 250,000 As described in Note 15, effective July 12, 2023, the Company issued Ms. Swartz a warrant to purchase an aggregate of 130,000 2.28 4.1% 5 167% 0% 296,400 28,817 As described in Note 11, during the period August 2023 through September 2023, the Company sold 2.9 Units (“Units”) to 4 investors in a private offering at a purchase price of $ 250,000 725,000 250,000 8% 7,813 0.001 20.00 As of October 31, 2023, there was approximately $ 4,881,000 All stock compensation expense is classified under general and administrative expenses in the consolidated statements of operations.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Oct. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 15 – COMMITMENTS AND CONTINGENCIES Skincare Agreement In September 2022, the Company entered into a joint development agreement and supply agreement with a third-party supplier (“Supplier”) that develops and manufactures various devices and related equipment and consumables used in the skincare industry (“Skincare Agreement”) that are marketed and sold directly and/or through its affiliates or third parties, in the United States of America and in most major international markets. Under the terms of the Skincare Agreement, the Company was obligated to provide and the Third Party was obligated to purchase a minimum volume of raw material ingredient (“Ingredient”) from the Company to be used as part of formulations in exclusive biologic topical products (“Products”) to be marketed and sold by Supplier during the first year of the Agreement in the amount of $ 167,000 During September 2023, the Company and the Supplier agreed to enter into an Amendment and Restatement of the Skincare Agreement (“Amended Skincare Agreement”). Under the terms of the Amended Skincare Agreement, the products to be provided by the Company was modified to include both the Ingredient and a topical moisturizer (“Moisturizer”) supplied by the Formulator (see Note 7). The Ingredient and the Moisturizer are hereinafter referred to as the “Combined Product”. The Supplier was obligated to deliver a purchase order for a minimum of $ 403,200 648,000 During November 2023, the Supplier paid the Company $ 403,200 235,200 Executive Employment Agreements The Company is party to executive employment agreements with each of Ian T. Bothwell (our Chief Financial Officer), Dr. Maria Ines Mitrani (our former Chief Science Officer) (see below) and Albert Mitrani, our former Executive Vice President of Sales) (see below), originally executed in April 2018 and subsequently amended (the “ Executive Employment Agreements 300,000 Pursuant to the terms of the SPA, the Executive Employment Agreements were further amended on August 19, 2022 and February 9, 2023 as follows: 1. Each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell amended their respective employment agreements providing for (a) setting their respective base salaries at $ 300,000 In the February 9, 2023 amendment, each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell agreed to a reduction in each executive’s annual salary to $ 150,000 200,000 2. Albert Mitrani and Dr. Maria Ines Mitrani each waived all accrued but unpaid compensation outstanding as of July 31, 2022. The Company, Albert Mitrani and Dr. Maria Ines Mitrani also agreed to terminate the leases with Mariluna LLC for use of Albert Mitrani’s and Mari Mitrani’s Miami, FL and Aspen, Colorado homes, retroactive to July 13, 2022. The Company wrote off the related ROU asset and lease liability as of the Closing Date. The balance of unpaid and accrued compensation that was forgiven by Albert Mitrani and Dr. Maria Ines Mitrani totaling $ 430,200 563,455 3. Ian Bothwell waived all unpaid and accrued compensation outstanding as of July 31, 2022, in exchange for ten-year warrants to purchase 150,000 4.00 455,478 4. Each of Albert Mitrani, Dr. Maria Ines Mitrani, Ian Bothwell and all other recipients agreed to terminate all awards granted but not yet issued under the Company’s Management and Consultant Performance Plan. 5. Each of Albert Mitrani, Dr. Maria Ines Mitrani and Ian Bothwell agreed to modify severance compensation provisions to be paid upon termination to only occur upon a termination without cause in an amount equal to one month’s base salary for each year of service. In connection with the February 9, 2023 amendment to the Executive Employment Agreements, Mr. Bothwell and Mr. Mitrani also agreed to repay approximately $ 44,600 84,300 On April 28, 2023, the Company terminated Dr. Maria Ines Mitrani as its Chief Scientific Officer and contemporaneously terminated her employment agreement with the Company. On May 12, 2023, the Company terminated Albert Mitrani as its Executive Vice President of Sales and contemporaneously terminated his employment agreement with the Company. As of October 31, 2023, the Company reserved the remaining amounts due of $ 0 75,900 As of October 31, 2023 and October 31, 2022, the total amounts due from related parties were $ 0 128,939 Resignation Of Matthew Sinnreich On July 21, 2022 (“Effective Date”), Matthew Sinnreich was appointed by the Board of Directors to the position of Chief Operating Officer and Acting Chief Executive Officer. On the Effective Date, Organicell and Mr. Sinnreich entered into a term sheet (the “Term Sheet”) setting forth in principle the terms of Mr. Sinnreich’s employment agreement with and compensation by the Company. The Term Sheet was subject to the negotiation and execution of a definitive employment agreement embodying the provisions of the Term Sheet, as well as customary terms and conditions for an executive employment agreement (the “Employment Agreement”). The parties agreed to use their respective commercial best efforts to negotiate and execute the Employment Agreement. In connection with the Term Sheet, as an inducement for Mr. Sinnreich to join the Company, Mr. Sinnreich was issued 50,000 200,000 6.80 During the first year of the Initial Term, Mr. Sinnreich was to be compensated by the issuance of 120,000 shares of Organicell’s common stock, which were to vest in equal monthly installments of 10,000 shares each (“Salary Shares”). During the second year of the Initial Term, Mr. Sinnreich was to be entitled to receive a base salary of $ 25,000 On September 13, 2022, Mr. Sinnreich assumed the position of President and Acting Chief Executive Officer. He subsequently resigned from the Company on November 22, 2022. During the period November 1, 2022 through November 22, 2022 and as of November 22, 2022, a total of 7,233 40,767 In July 2023, Mr. Sinnreich paid the Company $ 50,000 170,000 200,000 170,000 Chief Executive Officer, Chief Science Officer and Chief Products Officer On June 6, 2023, our board of directors appointed Harry Leider, M.D., M.B.A., as Chief Executive Officer and a member of the board of directors and Howard J. Golub, M.D., as Executive Vice President and Chief Science Officer. Ian T. Bothwell, who has served as Interim Chief Executive Officer since November 2022, in addition to his position as Chief Financial Officer will continue in his Chief Financial Officer role. On July 12, 2023, our board of directors appointed Jill Swartz, as Chief Products Officer. Dr. Leider’s employment agreement provides for a base salary of $ 325,000 285,000 2.40 Dr. Leider shall also be entitled to earn a commission of ten percent (10%) of the net profit (sales less cost of goods sold) generated by the sale of any of the Company’s biologic products sold directly by him solely from sources generated by him alone. Dr. Leider’s employment with the Company is “At Will” meaning that his employment with the Company and his employment agreement may be terminated by the Company at any time, for any reason or for no reason at all and with or without “Cause” (as defined in the Agreement). Notwithstanding the foregoing, in the event the Company terminates Dr. Leider’s employment without Cause or Dr. Leider terminates his employment with the Company for “Good Reason” (as defined in the Agreement), Dr. Leider will be entitled to receive an amount equal to one year’s salary as severance, less the value of the Leider Option as vested on the date of termination, as calculated by subtracting the market price for the shares underlying the option as of the date of termination, less the exercise price for such shares, provided further, that the combined amount of the severance payment and market value of the Leider Option shall not be less than $200,000. In such circumstance he will also be entitled to receive a pro-rated share of any bonus earned for the year in which the termination takes place. Dr. Golub’s employment agreement provides for a base salary of $ 150,000 Dr. Golub is also granted an option under the Incentive Plan to purchase 250,000 2.40 Dr. Golub’s employment with the Company is “At Will” meaning that his employment with the Company and his employment agreement may be terminated by the Company at any time, for any reason or for no reason at all and with or without “Cause” (as defined in the Agreement). Notwithstanding the foregoing, in the event the Company terminates Dr. Golub’s employment without Cause or Dr. Golub terminates his employment with the Company for “Good Reason” (as defined in the Agreement), Dr. Golub will be entitled to receive an amount equal to one year’s base salary as severance. He will also be entitled to receive a pro-rated share of any bonus earned for the year in which the termination takes place. Ms. Swartz’s employment agreement provides for a base salary of $ 215,000 130,000 2.40 Ms. Swartz’s employment with the Company is “At Will” meaning that her employment with the Company and her employment agreement may be terminated by the Company at any time, for any reason or for no reason at all and with or without “Cause” (as defined in the Agreement). Notwithstanding the foregoing, in the event the Company terminates Ms. Swartz’s employment without Cause or Ms. Swartz terminates her employment with the Company for “Good Reason” (as defined in the Agreement), Ms. Swartz will be entitled to receive an amount equal to one year’s base salary as severance. All the above employment agreements contain customary confidentiality, non-competition and non-solicitation covenants. Consultant Agreements Assure Immune LLC Effective March 29, 2021, the Company and Assure Immune L.L.C (“Consultant”) entered into an amendment (“Amendment”) to the consulting agreement between the parties dated March 30, 2020 (“Agreement”). Under the terms of the Amendment, the initial term of the Agreement was extended for an additional 2 years (until March 30, 2023) and the terms for eligibility of the Consultants to receive future grants of stock above those stock issuances granted as of the date of the Amendment based on achievement of certain future milestones previously provided for in the Agreement were eliminated. In addition, the Amendment provided additional terms in connection with termination of the Agreement. Under the terms of the Amendment, the Consultant received an additional 100,000 shares of common stock that vested 50% upon execution of the Amendment and the remaining 50% on December 31, 2021. On August 19, 2022 the Company and Consultant agreed to an amendment to the consulting agreement whereby the Consultant was issued 25,000 shares of common stock of the Company and received a $20,000 cash payment in exchange for satisfaction of approximately $200,000 in outstanding consulting fees due to the Consultant up through August 31, 2022. The parties also agreed to the reduction of future fees payable to the Consultant from $40,000 per month to $15,000 per month for the period September 2022 through March 2023. The Agreement was not renewed upon its expiration. Preparation of IRB, Pre-IND, IND Protocols for Clinical Applications and Clinical Trial Initiation and Monitoring In connection with the Company’s ongoing research and development efforts and the Company’s efforts to meet compliance with current and anticipated United States Food and Drug Administration (“FDA”) regulations pertaining to marketing traditional biologics and human cells, tissues and cellular and tissue based products that fall under Section 351 of the Public Health Services Act (“HCT/Ps”), the Company has applied for and received Investigation New Drug (“IND”) approval from the FDA to commence clinical trials in connection with the use of the Company’s products and related treatment protocols for specific indications. New CRO Agreements During August 2021, October 2021, and December 2021, the Company entered into agreements with a new CRO to provide ongoing clinical research and related services in connection with two of the Company’s approved clinical research trials (“New CRO Agreements”). On August 23, 2022 the New CRO Agreements were amended. In connection with the New CRO Agreements, the Company is obligated to make aggregate payments to the CRO of approximately $1,443,000 plus estimated aggregate pass-through costs and other third-party direct costs of approximately $495,000 (“Pass-Through Costs”) as well as site and patient related costs. The Company is obligated to make the CRO payments based on the actual costs incurred over the term of the clinical trial beginning on the commencement of the work by the CRO in connection with the applicable clinical trial and the payments for the pass-through costs and other third-party direct costs as well as site and patient related costs are paid in accordance with completion of agreed upon milestones. In connection with the two aforementioned studies, the Company determined in one of the studies that it acquired sufficient safety data with less than the originally planned patient enrollment and the study has been closed. In the other study, the Company is reviewing the benefit from continued efforts to commence the study and/or whether the existing approved IND should be modified, terminated and/or replaced. As of October 31, 2023, the Company has been billed a total of approximately $1,431,300 in connection with the New CRO Agreements, Pass-Through Costs and Site related costs, respectively, of which approximately $ 587,800 As of October 31, 2022, the Company has been billed a total of approximately $680,000 in connection with the New CRO Agreements, including $18,400 of escrow related payments, of which approximately $ 244,900 Contingent Convertible Obligations Into Equity Securities Obligations Due Under Executive Employment Agreements In connection with the Closing, the Company and each of the Executives agreed to forego their unpaid Original Base Salary and Incremental Salary (see “Changes in Management Compensation” above). Legal Matters SEC Matter On June 17, 2021, Organicell received a subpoena dated June 14, 2021, from the Atlanta Regional Office of the SEC requiring the production of certain documents and communications in connection with the treatment and results of various COVID-19 patients, as discussed in the Company’s Current Reports on Form 8-K filed with the SEC during the period from May 27, 2020 through May 11, 2021. The Company fully cooperated with the SEC’s investigation and believes that it has provided all of the information requested by the SEC. The Company can make no assurances as to the time or resources that will need to be devoted to this investigation in the future or its final outcome, or the impact, if any, of this investigation or any proceedings on the Company’s current business, financial condition, results of operations, cash flows, or the Company’s future operations. LAE International Consulting On August 17, 2021, the Company was served with a summons and complaint by LAE International Consulting, LLC (“LAE”), in the case styled LAE International Consulting, LLC v. Organicell Regenerative Medicine, Inc. et al., Case No. 2021-018461-CA-01 (In the Circuit Court of the 11th Judicial Circuit in and for Miami Dade County, Florida) 45,000 2,000,000 Daniel Pepock and Tracy Yourke The Company terminated the employment agreements with the former Sales Executives Daniel Pepock (“Pepock”) and Tracy Yourke (“Yourke”) effective June 30, 2022. On August 22, 2022, Mr. Pepock, Ms. Yourke and Organicell agreed to a material settlement term sheet (“Settlement”) which provided for the resolution and full settlement and release of all claims among the parties and for the Company to buy back all of the shares of common stock of the Company issued to and owned by Mr. Pepock and Ms. Yourke at the time of the Settlement (represented by Mr. Pepock and Ms. Yourke to be in excess of 124,000 shares) in exchange for a payment by the Company of $500,000 (“Purchase Price”). In addition, the Company agreed to release Mr. Pepock and Ms. Yourke from their non-compete restrictions upon transfer of the shares to the Company. Effective October 13, 2022, the parties executed a Confidential Settlement Agreement and Mutual General Release memorializing the terms of the Settlement. Under the terms of the Settlement, the Company agreed to repurchase 124,000 shares of common stock for $500,000. On January 31, 2023, 124,000 shares were transferred to the Company and the Company paid the Purchase Price. The shares received by the Company were immediately cancelled and returned to the Company’s treasury of authorized and unissued shares on February 3, 2023. At October 31, 2022, the Company has recorded the obligation to repurchase the shares in connection with settlement of the litigation in the amount of $500,000 in the consolidated balance sheet. Albert Mitrani and Dr. Maria Ines Mitrani On June 7, 2023, Organicell filed a four-count complaint with the Seventeenth Judicial Circuit in and for Broward County, Florida against Albert Mitrani and Dr. Maria Ines Mitrani, co-founders of the Company. Albert Mitrani was a former director and executive officer of the Company (most recently serving as Chief Executive Officer from September 2019 to July 2022 and as Executive Vice President of Sales from July 2022 until his termination in May 2023) and Dr. Mitrani is a former director and former executive officer of the Company (serving as Chief Science Officer from November 2016 until her termination in April 2023). The complaint alleges (i) breach of contract; (ii) breach of fiduciary duty; and (iii) tortious interference with business relationships; and seeks injunctive relief, in connection with, inter alia Effective November 13, 2023, the Company entered into a settlement agreement with Albert Mitrani and Dr. Maria Ines Mitrani, pursuant to which it resolved various claims against the Mitranis, including those set forth in the previously reported Florida state action the Company had filed against the Mitranis. As part of the settlement, Albert Mitrani and Dr. Maria Ines Mitrani returned to the Company 682,161 and 481,831 shares of Organicell common stock held by them respectively and the parties exchanged mutual releases. Other In addition to the foregoing, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Oct. 31, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	NOTE 16 – SEGMENT INFORMATION For the years ended October 31, 2023 and 2022, the Company operated only one 1

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Oct. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Concentrations of Risk	Concentrations of Risk Credit Risk The balance sheet items that potentially subject us to concentrations of credit risk are primarily cash and cash equivalents and accounts receivable. Balances in accounts are insured up to Federal Deposit Insurance Corporation (“FDIC”) limits of $ 250,000 915,497 Major Customer During the year ended October 31, 2023, the Company sold products and services totaling approximately $ 1,301,000 28.5% 459,000 10.1% 460,000 10.1% During the fiscal year ended October 31, 2022, the Company sold a total of approximately $ 2,124,000 32.7% 1,413,700 21.8% 702,100 10.8% The Company’s sales agreements are non-exclusive and the Company does not believe it has any exposure based on the customers of its products. Major Supplier During the fiscal year ended October 31, 2023, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 113,100 86,900 57.0% 43.0% During the fiscal year ended October 31, 2022, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 145,000 130,000 53.0% 47.0% The Company’s supply agreements are non-exclusive and the Company does not believe it has any exposure based on the availability of raw materials and/or products from other suppliers.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles of the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Management bases its estimates on historical experience and on other assumptions considered to be reasonable under the circumstances. However, actual results may differ from the estimates. Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services, and assumptions used in the determination of the Company’s liquidity.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at net realizable value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. Management determined that no 0 27,500
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value using the average cost method. The Company provides a reserve for potential excess, dated or obsolete inventories based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. At October 31, 2023 and 2022, the Company determined that no 37,455
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of property and equipment range from 3 15
Non-marketable Securities	Non-marketable Securities Non-marketable securities consist of equity investments in privately held companies, which are classified as other assets on the consolidated balance sheets. These non-marketable equity securities do not have readily determinable fair values. Under the measurement alternative election, the Company accounts for these non-marketable securities at cost and adjusted for observable price changes in orderly transactions for the identical or similar investments of the same issuer or upon impairment and are not eligible for the net-asset-value practical expedient from fair value measurement. The measurement alternative election is reassessed each reporting period to determine whether the non-marketable securities continue to be eligible for this election. The Company periodically evaluates its non-marketable securities for impairment when events and circumstances indicate that the carrying amount of the investment may not be recovered. Impairment indicators may include, but are not limited to, a significant deterioration in earnings performance, credit rating, asset quality or business outlook or a significant adverse change in the regulatory, economic, or technological environment. Under current U.S. GAAP, equity investments without readily determinable fair values are reported at cost minus impairment. However, impairment losses are recognized only if they are considered other-than- temporary. The Company evaluated its investment in non-marketable securities at October 31, 2023, and determined such investment was impaired.
Leasehold Improvements	Leasehold Improvements Leasehold improvements in excess of $1,000 that are made in connection with leases having a term of more than 12 months are capitalized by the Company and amortized over the shorter of the useful life of the asset or the remaining lease periods and renewals that are deemed to be reasonably certain at the date the leasehold improvements are purchased. Costs associated with leasehold improvements that do not exceed $1,000 are expensed as incurred.
Revenue Recognition	Revenue Recognition The Company follows the guidance of FASB Accounting Standards Update (“ASU”) Topic 606 “Revenue from Contracts with Customers” which requires the Company to recognize revenue in amounts that reflect the prorata completion of the performance obligations of the Company required under the contracts. The Company recognizes revenue only when it transfers control of a promised good or service to a customer in an amount that reflects the consideration it expects to receive in exchange for the good or service. Our performance obligations are satisfied and control is transferred at a point-in-time, which is typically when the transfer and title to the product sold has taken place and there is evidence of our customer’s satisfactory acceptance of the product shipment or delivery except in those instances when the customer has made prior arrangements with the Company to store the product purchased by the customer at the Company’s facilities that is to be delivered at a later date to be designated by the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the Company’s consolidated balance sheet.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic income (loss) per common share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of fully vested common shares outstanding during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of fully vested shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted average number of shares adjusted for any potentially dilutive debt or equity instruments. At October 31, 2023, the Company had 2,571,656 100,000 2,149,000 499,216
Stock-Based Compensation	Stock-Based Compensation All stock-based payments are recognized in the financial statements based on their fair values. The Company periodically issues stock options and stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.
Research and Development Costs	Research and Development Costs Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred. Our research and development expenses were approximately $ 922,700 791,300
Income Taxes	Income Taxes The Company files a consolidated tax return that includes all of its subsidiaries. Provisions for income taxes are based on taxes payable or refundable for the current year taxable income for federal and state income tax reporting purposes and deferred income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis and operating loss carryforwards. Deferred income tax expense represents the change during the period in the deferred tax assets and deferred tax liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of the operations in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company accounts for uncertain tax positions in accordance with FASB Topic 740 – Income Taxes. This pronouncement prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. The interpretation also provides guidance on recognition, derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. For the years ended October 31, 2023 and 2022 the Company incurred operating losses, and therefore, there was not any income tax expense amount recorded during those periods. There is a full valuation allowance established for the tax benefit associated with the net losses for the years ended October 31, 2023 and 2022.
Valuation of Derivatives	Valuation of Derivatives The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date.
Sequencing	Sequencing The Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. The Company currently has 2,500,000,000 7,283,483
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company includes fair value information in the notes to financial statements when the fair value of its financial instruments is different from the book value. When the book value approximates fair value, no additional disclosure is made. The Company follows FASB ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measurements. It defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company’s financial instruments consist of cash and cash equivalents, accounts payable, accrued liabilities and convertible debt. The estimated fair value of cash, accounts payable and accrued liabilities approximate their carrying amounts due to the short-term nature of these instruments. The Company follows the provisions of ASC 820 with respect to its financial instruments. As required by ASC 820, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Level one Level two Level three The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.
Operating Lease Obligations	Operating Lease Obligations Under the provisions of Accounting Standards Update (ASU) No. 2016-02 (Topic 842) (“ASC 842”), the Company recognizes a right of use (“ROU”) asset and corresponding lease liability for all operating leases upon commencement of the lease. The Company’s policy is to treat operating leases that have a term of one year or less at lease commencement date and do not include a purchase option that is reasonably certain of exercise, consistent with the lease recognition approach as previously outlined under ASC 840. In addition, month to month leases which do not involve additional financial commitments on the part of the Company are also treated consistent with the lease recognition approach as previously outlined under ASC 840. The Company has established a capitalization threshold of $ 15,000
Subsequent Events	Subsequent Events The Company has evaluated subsequent events that occurred after October 31, 2023 through the financial statement issuance date for subsequent event disclosure or recording.

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Oct. 31, 2023
Inventory Disclosure [Abstract]
Schedule of inventories	Schedule of inventories October 31, October 31, Raw materials and supplies $ 153,868 $ 85,096 Finished goods 156,315 163,414 Total inventories $ 310,183 $ 248,510

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Oct. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Schedule of property and equipment October 31, October 31, Computer equipment $ - $ 26,881 Finance lease equipment 260,356 544,378 Manufacturing equipment 534,531 625,979 Leasehold improvements - 925,932 794,887 2,123,170 Less: accumulated depreciation and amortization (222,161 ) (439,654 ) Total property and equipment, net $ 572,726 $ 1,683,516

EQUITY IN NON-MARKETABLE SECU_2

EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY (Tables)	12 Months Ended
	Oct. 31, 2023
Equity In Non-marketable Securities Of Affiliated Entity
Schedule of equity in non marketable securities affiliated entity	Schedule of equity in non marketable securities affiliated entity October 31, October 31, Equity in non-marketable securities $ 100,000 - Reserve on carrying value of investment in non-marketable securities $ (100,000 ) - Equity in non-marketable securities $ - -

LEASE OBLIGATIONS (Tables)

LEASE OBLIGATIONS (Tables)	12 Months Ended
	Oct. 31, 2023
Lease Obligations
Schedule of minimum lease payment to finance lease	Schedule of minimum lease payment to finance lease Year Ended October 31, Minimum 2024 $ 23,588 2025 5,536 2026 5,536 2027 2,768 2028 - Thereafter - Total undiscounted finance lease payments 37,428 Less: imputed interest (1,187 ) Present value of finance lease liabilities $ 36,241

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Oct. 31, 2023
Payables and Accruals [Abstract]
Schedule of account payable and accrued expenses	Schedule of account payable and accrued expenses October 31, October 31, Accrued payroll related liabilities $ 666,924 $ 666,780 Lab equipment and supplies payables 407,183 477,255 Clinical trial and research payables 675,284 312,711 Legal fees payables 478,810 328,121 Other professional fees payables 81,135 90,993 Accrued IRS penalty (Note 12) 86,319 83,684 Accrued commissions payable 101,627 39,675 Construction payables 9,317 5,474 Other payables and accrued expenses 105,370 373,838 Total Accounts Payable and Accrued Expenses $ 2,611,969 $ 2,378,531

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Oct. 31, 2023
Debt Disclosure [Abstract]
Schedule of notes payable	Schedule of notes payable October 31, October 31, SPA 22 $ - $ 600,000 SPA 23 - - Convertible Promissory Notes 725,000 - Unamortized discount (68,147 ) (36,889 ) Total Notes Payable $ 656,853 $ 563,111

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Oct. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of provision for income tax	Schedule of provision for income tax Year Ended Year Ended Current: Federal $ - $ - State - - Current Income Tax Expense (Benefit) $ - $ - Deferred: Federal $ (385,315 ) $ 4,405,121 State (349,335 ) 1,079,723 Deferred Income Tax Expense (Benefit) (734,650 ) 5,484,844 Change in Valuation Allowance 734,650 (5,484,844 ) Income tax provision $ - $ -
Schedule of effective income tax rate	Schedule of effective income tax rate October 31, October 31, Tax at federal statutory rate $ (1,467,209 ) $ (1,868,277 ) State taxes, net of federal benefit (349,335 ) (386,555 ) Permanent differences - 400,100 Stock-based compensation 834,282 6,609,802 Executive Forgiveness of employment obligations In connection with Restructuring - 480,109 Other 247,612 249,665 Total income tax expense (benefit) (734,650 ) 5,484,844 Change in valuation allowance 734,650 (5,484,844 ) Income tax provision $ - $ -
Schedule of deferred tax assets and liabilities	Schedule of deferred tax assets and liabilities October 31, October 31, Deferred Tax Assets: Stock based compensation $ 1,636,853 $ 798,239 Net operating loss carryforward-Federal 3,611,327 3,002,402 Net operating loss carryforward-State 617,525 396,530 Other - 1,477 Total deferred tax assets: 5,865,705 4,198,648 Deferred Tax Liabilities: Property and equipment 309,260 302,447 Total deferred tax liabilities: 309,260 302,447 Valuation Allowance (5,556,445 ) (3,896,201 ) Net deferred tax assets $ - $ -

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	12 Months Ended
	Oct. 31, 2023
Equity [Abstract]
Schedule of non vested share activity	Schedule of non vested share activity Number of Weighted- Outstanding at October 31, 2022 499,216 $ 11.35 Non-Vested Shares Granted - $ - Vested 169,983 $ 12.19 Expired/Forfeited 229,233 $ 10.35 Outstanding at October 31, 2023 100,000 $ 12.20 Number of Weighted- Outstanding at October 31, 2021 419,222 $ 12.34 Non-Vested Shares Granted 129,500 $ 6.86 Vested 49,506 $ 7.98 Expired/Forfeited - $ - Outstanding at October 31, 2022 499,216 $ 11.35

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Oct. 31, 2023
Warrants
Schedule of warrant activity	Schedule of warrant activity Number of Weighted- Remaining Aggregate Outstanding at October 31, 2022 2,149,000 $ 4.52 9.63 $ 2,440,110 Granted 737,656 $ 3.57 5.00 $ - Exercised - $ - - $ - Expired/Forfeited (315,000 ) $ 6.62 8.46 $ - Outstanding at October 31, 2023 2,571,656 $ 3.99 7.50 $ - Exercisable at October 31, 2023 1,959,365 $ 4.45 8.33 $ - Number of Weighted- Remaining Aggregate Outstanding at October 31, 2021 47,500 $ 6.11 6.90 $ 289,500 Granted 2,101,500 $ 4.48 10.0 $ - Exercised - $ - - $ - Expired/Forfeited - $ - - $ - Outstanding at October 31, 2022 2,149,000 $ 4.52 9.63 $ 2,440,110 Exercisable at October 31, 2022 1,940,242 $ 4.37 9.62 $ 2,403,058

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Product Information [Line Items]
FDIC limits per institutions	$ 250,000
Cash Balances	915,497
Revenues	4,558,278	$ 6,491,008
Cost of revenues	507,629	753,534
Allowance for bad debts	0	0
Bad debt expense	0	27,500
Inventory Reserve	0	37,455
Research and Development Expense	$ 922,700	$ 791,300
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	7,283,483	7,395,632
Common stock, shares outstanding	7,283,483	7,395,632
Operating and finance lease obligation	$ 15,000
Common Shares Issuable Upon Exercise Of Warrants [Member]
Product Information [Line Items]
Antidilutive securities excluded from computation of earnings per share	2,571,656	2,149,000
Unvested Restricted Stock [Member]
Product Information [Line Items]
Antidilutive securities excluded from computation of earnings per share	100,000	499,216
Minimum [Member]
Product Information [Line Items]
Property, plant and equipment, estimated useful lives	3 years
Maximum [Member]
Product Information [Line Items]
Property, plant and equipment, estimated useful lives	15 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Large distributor and distributors customers [Member]
Product Information [Line Items]
Revenues	$ 1,301,000	$ 2,124,000
Concentration credit risk percentage	28.50%	32.70%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | A large distributor and the distributors customers [Member]
Product Information [Line Items]
Revenues	$ 459,000
Concentration credit risk percentage	10.10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Individual Medical Practice [Member]
Product Information [Line Items]
Revenues	$ 460,000
Concentration credit risk percentage	10.10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customers of another distributor [Member]
Product Information [Line Items]
Revenues		$ 1,413,700
Concentration credit risk percentage		21.80%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Management Services Organization [Member]
Product Information [Line Items]
Revenues		$ 702,100
Concentration credit risk percentage		10.80%
Tissue Raw Material [Member] | Customer Concentration Risk [Member] | First Supplier [Member]
Product Information [Line Items]
Concentration credit risk percentage	57%	53%
Cost of revenues	$ 113,100	$ 145,000
Tissue Raw Material [Member] | Customer Concentration Risk [Member] | Second Supplier [Member]
Product Information [Line Items]
Concentration credit risk percentage	43%	47%
Cost of revenues	$ 86,900	$ 130,000

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 6,986,708	$ 8,896,557
Cash from operating activities	2,197,275	3,165,840
Accumulated deficit	57,508,014	50,521,306
Stockholders' deficit	1,241,019	$ (1,888,604)	$ 2,665,593
Working capital deficit	$ 1,807,926

RESTRUCTURING (Details Narrativ

RESTRUCTURING (Details Narrative) - USD ($)		1 Months Ended
	Jul. 13, 2022	Aug. 19, 2022	Jul. 21, 2022	Jul. 16, 2022	Mar. 17, 2022	Dec. 27, 2021	Jun. 04, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share price						$ 5.80	$ 27.20
Letter of intent description				Skycrest/Greyt Group and Beyond 100 each advanced Organicell $400,000 and $300,000, respectively (a total of $700,000) as good faith deposits against the $2,000,000 (a total of $4,000,000) purchase price for the Shares.
Consulting Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock purchased		25,000
Share price					$ 3.60
Skycrest Holdings [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment	$ 2,000,000
Number of common stock purchased	500,000
Share price	$ 4
Beyond 100 FZE [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment				$ 2,000,000
Number of common stock purchased				500,000
Share price				$ 4
Skycrest [Member] | Consulting Agreement [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of warrants purchased			750,000
Exercise Price			$ 4

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 153,868	$ 85,096
Finished goods	156,315	163,414
Total inventories	$ 310,183	$ 248,510

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 794,887	$ 2,123,170
Less: accumulated depreciation	(222,161)	(439,654)
Total property and equipment, net	572,726	1,683,516
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		26,881
Finance lease equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	260,356	544,378
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	534,531	625,979
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 925,932

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)		12 Months Ended
	Aug. 07, 2023	Oct. 31, 2023	Oct. 31, 2022
Property, Plant and Equipment [Line Items]
Sale of equipment and leaseholds		$ 25,391	$ 824,743
Finance lease obligations		36,241
Gain on sale of plant		(36,219)
Depreciation expense		106,384	82,036
Amortization expense		$ 379,970	$ 250,472
Purchaser [Member]
Property, Plant and Equipment [Line Items]
Purchase price paid	$ 1,252,000
Finance lease obligations	213,261
Gain on sale of plant	340,611
Transaction fees	11,100
Purchaser [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Sale of equipment and leaseholds	752,000
Purchases of inventory	$ 500,000

EQUITY IN NON-MARKETABLE SECU_3

EQUITY IN NON-MARKETABLE SECURITIES OF AFFILIATED ENTITY (Details) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Equity In Non-marketable Securities Of Affiliated Entity
Equity in non-marketable securities	$ 100,000
Reserve on carrying value of investment in non-marketable securities	(100,000)
Equity in non-marketable securities

LEASE OBLIGATIONS (Details)

LEASE OBLIGATIONS (Details)	Oct. 31, 2023 USD ($)
Lease Obligations
2024	$ 23,588
2025	5,536
2026	5,536
2027	2,768
2028
Thereafter
Total undiscounted finance lease payments	37,428
Less: imputed interest	(1,187)
Present value of finance lease liabilities	$ 36,241

LEASE OBLIGATIONS (Details Narr

LEASE OBLIGATIONS (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Sep. 30, 2023	Mar. 31, 2021	Mar. 31, 2019	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021	Aug. 07, 2023	Jul. 02, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finance lease obligations				$ 36,241
Finance lease obligations current				23,107	$ 143,748
Operating lease obligation					82,407
Lease expense					29,670
Security deposit				7,315	39,936
Mari Luna [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Minimum monthly lease payments								$ 3,500
Operating lease obligation								$ 117,659
Borrowing rate								4.50%
Security deposit				5,000
Basalt Lab Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease obligation		$ 235,313		0
Borrowing rate		4.50%
Lease expense		$ 6,800
Right of use asset					110,955
Purchaser [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Finance lease obligations							$ 213,261
Written off ROU asset and corresponding liability							$ 49,750
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment to acquire			$ 239,595			$ 304,873
Monthly payments			$ 4,513			$ 5,478
Operating leased equipment, per unit			1			1
Annual interest rate			4.50%			3%
Estimated useful lives of leased equipment			15 years			15 years
Finance lease obligations				36,241
Finance lease obligations current				$ 23,107
Weighted average remaining term of Finance Leases				7 months 12 days
Second Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Security deposit		$ 20,400		$ 11,000
Basalt Lab Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease expense				$ 61,246	$ 76,351
Security deposit returned	$ 20,400

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Jun. 30, 2022	Oct. 31, 2020	Jul. 31, 2020	Oct. 31, 2023	Oct. 31, 2022	Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Security deposit				$ 7,315	$ 39,936
Rent expenses				0	31,500
Payment for certain expenses				$ 0	36,352
Unpaid and accrued compensation description				Ian Bothwell waived all unpaid and accrued compensation in the amount of $1,043,478, in exchange for ten-year warrants to purchase 150,000 Shares at an exercise price of $4.00 per share, exercisable on a “cashless basis” and a cash payment of $50,000 at Closing. At Closing, Dr. George Shapiro terminated his consulting arrangement with the Company and waived all unpaid consulting fee obligations in the amount of $139,500 in exchange for ten-year warrants to purchase 15,750 Shares at an exercise price of $4.00 per share, exercisable on a “cashless basis.”
Cash invested in non-marketable equity securities				$ 100,000
Option acquire description				the Company’s CMO was granted an option to acquire up to 200,000 membership interests in the Formulator, of which 100,000 vested immediately and the remaining $100,000 will vest based on future sales of the Formulator attributed to the CMO. The option price is $20,000 for the 200,000 membership interests (see Note 7).
Advances payable				$ 220,897	220,897
Michael Carbonara [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related parties					101,715
Albert Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Capital contribution	$ 250,000
Second Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Security deposit				11,000		$ 20,400
Monthly rent expense		$ 6,500
Rent expenses				0	58,500
Executive Employment Agreements [Member] | Albert Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unpaid and accrued compensation forgiven				430,200
Executive Employment Agreements [Member] | Dr. Mari Mitrani [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unpaid and accrued compensation forgiven				563,455
Mari Luna [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Security deposit				5,000
Monthly rent expense			$ 3,500
Management Services Organization [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceed from sale of products				$ 180,900	$ 702,100

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Payables and Accruals [Abstract]
Accrued payroll related liabilities	$ 666,924	$ 666,780
Lab equipment and supplies payables	407,183	477,255
Clinical trial and research payables	675,284	312,711
Legal fees payables	478,810	328,121
Other professional fees payables	81,135	90,993
Accrued IRS penalty (Note 12)	86,319	83,684
Accrued commissions payable	101,627	39,675
Construction payables	9,317	5,474
Other payables and accrued expenses	105,370	373,838
Total Accounts Payable and Accrued Expenses	$ 2,611,969	$ 2,378,531

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Debt Disclosure [Abstract]
SPA 22		$ 600,000
SPA 23
Convertible Promissory Notes	725,000
Unamortized discount	(68,147)	(36,889)
Total Notes Payable	$ 656,853	$ 563,111

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)				1 Months Ended			6 Months Ended	12 Months Ended
	Mar. 06, 2023 USD ($)	Feb. 10, 2023 USD ($) $ / shares shares	Jun. 04, 2021 $ / shares shares	Sep. 30, 2023 USD ($) Integer $ / shares shares	Jan. 24, 2022 USD ($)	Nov. 30, 2021 shares	Jan. 11, 2023 USD ($)	Mar. 06, 2024 USD ($)	Oct. 31, 2023 USD ($) $ / shares shares	Oct. 31, 2022 USD ($)	Jul. 11, 2022	Jan. 11, 2022 USD ($)	Dec. 27, 2021 $ / shares
Debt Instrument [Line Items]
Promissory note									$ 725,000
Interest rate											10%
Number of shares issued | shares			5,000			15,000
Share price | $ / shares			$ 27.20										$ 5.80
Repayment of promissory note									300,000
Promissory note discount									656,853	563,111
Common stock issued as commitment fee for Promissory Note	$ 169,500								282,500	156,231
Commitment Fee Shortfall Obligation										143,769
Commitment fee discount									349,272	323,111
Commitment fee shortfall obligation		$ 187,519								174,462
Conversion of stock, shares issued | shares		58,600
Conversion price | $ / shares		$ 3.20
Commitment Fee		$ 30,468
Legal fees								$ 15,000
Proceeds from note payble								$ 504,400	1,229,400	540,000
Original issue discount									68,147	36,889
Debt amortized discount									308,000
Warrant [Member]
Debt Instrument [Line Items]
Warrants issued									80,469
4 Investors [Member]
Debt Instrument [Line Items]
Principal amount				$ 250,000
Interest rate				8%
Warrants issued				$ 250,000
Aggregate purchase price				$ 725,000
Common stock purchase warrants | shares				7,813
4 Investors [Member] | Warrant [Member]
Debt Instrument [Line Items]
Conversion price | $ / shares				$ 6
Common stock par value | $ / shares				0.001
Exercise price | $ / shares				$ 20
Trading days | Integer				20
Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principal amount												$ 600,000
Discount												$ 60,000
Commitment fee									$ 123,000
Number of shares issued | shares									15,385
Share price | $ / shares									$ 8
Unsecured Promissory Note [Member]
Debt Instrument [Line Items]
Unpiad professional fees					$ 278,340
Promissory note					256,000
Cash payment					166,000
Periodic payment					7,500
Payments for notes receivable					$ 22,340
Additional Commitment [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Commitment fee									$ 33,231
Number of shares issued | shares									7,692
Share price | $ / shares									$ 4.32
Promissory Note [Member]
Debt Instrument [Line Items]
Discount									$ 60,000
Promissory note discount									260,000
Common stock issued as commitment fee for Promissory Note									123,000
Commitment Fee Shortfall Obligation									77,000
Additional promissory note discount							$ 100,000
Additional Fair value of Commitment Fee Share							33,231
Additional Commitment fee shortfall obligation							$ 66,769
Commitment fee discount									36,889	323,111
Fair value of Commitment Fee Share		$ 76,200							49,384	125,500
Commitmnet shortfall obligation										30,692
Commitment fee shortfall obligation									0	$ 174,462
Promissory Note SPA 23 [Member]
Debt Instrument [Line Items]
Principal amount	$ 530,000
Interest rate	12%
Promissory note discount									308,000
Common stock issued as commitment fee for Promissory Note									169,500
Original issue discount									10,600
Transaction fees									15,000
Fair value of warrant shares									$ 113,000
Promissory Note SPA 23 [Member] | Commitment Fee Shares [Member]
Debt Instrument [Line Items]
Number of shares issued | shares									75,000
Promissory Note SPA 23 [Member] | Warrant Shares [Member]
Debt Instrument [Line Items]
Number of shares issued | shares									50,000
Share price | $ / shares									$ 12

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Current:
Federal
State
Current Income Tax Expense (Benefit)
Deferred:
Federal	(385,315)	4,405,121
State	(349,335)	1,079,723
Deferred Income Tax Expense (Benefit)	(734,650)	5,484,844
Change in Valuation Allowance	(734,650)	5,484,844
Income tax provision

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ (1,467,209)	$ (1,868,277)
State taxes, net of federal benefit	(349,335)	(386,555)
Permanent differences		400,100
Stock-based compensation	834,282	6,609,802
Executive Forgiveness of employment obligations In connection with Restructuring		480,109
Other	247,612	249,665
Total income tax expense (benefit)	(734,650)	5,484,844
Change in valuation allowance	734,650	(5,484,844)
Income tax provision

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	Oct. 31, 2023	Oct. 31, 2022
Deferred Tax Assets:
Stock based compensation	$ 1,636,853	$ 798,239
Net operating loss carryforward-Federal	3,611,327	3,002,402
Net operating loss carryforward-State	617,525	396,530
Other		1,477
Total deferred tax assets:	5,865,705	4,198,648
Deferred Tax Liabilities:
Property and equipment	309,260	302,447
Total deferred tax liabilities:	309,260	302,447
Valuation Allowance	(5,556,445)	(3,896,201)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2011
Income Tax Disclosure [Abstract]
Statutory income tax rate	21%	21%
Federal operating loss carryforward	$ 17,196,794
State operating loss carryforward	12,025,813
State operating loss carryforward indefinitely	6,554,845
Penalties	90,000		$ 20,000
Accrued tax penalties	$ 86,319	$ 83,684

CAPITAL STOCK (Details)

CAPITAL STOCK (Details) - $ / shares	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Equity [Abstract]
Number of Nonvested Shares, Outstanding at beginning	499,216	419,222
Weighted-Average Grant Date Value, Outstanding at beginning	$ 11.35	$ 12.34
Number of Non-Vested Shares, Granted		129,500
Weighted-Average Grant Date Value, Granted		$ 6.86
Number of Non-Vested Shares, Vested	169,983	49,506
Weighted-Average Grant Date Value, Vested	$ 12.19	$ 7.98
Number of Non-Vested Shares, Expired/Forfeited	229,233
Weighted-Average Grant Date Value, Expired/Forfeited	$ 10.35
Number of Nonvested Shares, Outstanding at ending	100,000	499,216
Weighted-Average Grant Date Value, Outstanding at ending	$ 12.20	$ 11.35

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - USD ($)						1 Months Ended																12 Months Ended
	Mar. 06, 2023	Dec. 01, 2022	Oct. 13, 2022	Jan. 11, 2022	Jun. 04, 2021	Dec. 29, 2022	Dec. 27, 2022	Nov. 22, 2022	Aug. 31, 2022	Aug. 19, 2022	Jul. 21, 2022	Apr. 30, 2022	Mar. 17, 2022	Feb. 28, 2022	Jan. 31, 2022	Dec. 27, 2021	Nov. 30, 2021	Oct. 31, 2021	Feb. 28, 2021	Oct. 31, 2020	Jun. 30, 2020	Oct. 31, 2023	Oct. 31, 2022	Aug. 01, 2022	Jul. 21, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized																						10,000,000
Preferred stock, par value																						$ 0.001
Common stock shares converted																						$ 100,000	$ 7,270,000
Share price					$ 27.20											$ 5.80
Stock based compensation																						3,208,776	3,916,590
Shares vested								7,233
Stock issued for services, shares																5,000
Stock issued																						100,000	7,290,000
Stock-based compensation expense							$ 22,958															100,211
Stock issued during period					5,000												15,000
Stock granted of period value					$ 136,000											$ 29,000						201,000
Annual salary																180,000
Increasing annual salary																$ 210,000
Cash provided for credit facility																	$ 0
Purchase of restricted common shares																	35,000
Share price																	$ 10
Common stock shares converted	75,000			15,385
Common stock issued as commitment fee for Promissory Note	$ 169,500																					282,500	$ 156,231
Lawsuit settlement by cash												$ 45,000										$ 45,000
Lawsuit settlement by issuance of restricted common stock												10,000										2,000,000
Settlement of Litigation												$ 43,800
Number of common stock repurchase			124,000
Repurchase value			500,000
Common stock shares issued																						7,283,483	7,395,632
Common stock shares outstanding																						7,283,483	7,395,632
N2 2021 Plan [Member]
Class of Stock [Line Items]
Maximum aggregate number of shares																		1,250,000
2021 Plan [Member]
Class of Stock [Line Items]
Common stock shares issued																							417,000
Common stock shares outstanding																							417,000
Promissory Note [Member]
Class of Stock [Line Items]
Common stock issued as commitment fee for Promissory Note																						$ 123,000
Employee [Member]
Class of Stock [Line Items]
Share price		$ 6
Stock based compensation																						4,500
Number of shares granted		750
Service Provider [Member]
Class of Stock [Line Items]
Share price						$ 4
Stock granted of period value						$ 100,000
Number of shares granted						25,000
Consulting Agreement [Member]
Class of Stock [Line Items]
Share price													$ 3.60
Stock based compensation																						126,000
Stock granted of period value													$ 126,000
Number of unregistered common stock issued													35,000
Number of common stock issued										25,000
Proceeds from stock issued										$ 20,000
Consulting Agreement [Member] | Sinnreich [Member]
Class of Stock [Line Items]
Share price																				$ 2.70	$ 3.80				$ 6.80
Stock based compensation																						59,300	$ 343,000
Number of unregistered common stock issued																				10,000	8,500
Number of restricted common stock vested											50,000
Consulting Agreement [Member] | Third Party [Member]
Class of Stock [Line Items]
Stock based compensation																						35,146	25,104
Consulting Agreement 1 [Member] | Sinnreich [Member]
Class of Stock [Line Items]
Stock based compensation																						228,353	49,618
One Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued														41,667	3,333		40,000
Sale of stock, price per share														$ 6	$ 6		$ 10
Common stock shares converted														$ 250,000	$ 20,000		$ 400,000
Several Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued														1,000,000
Sale of stock, price per share															$ 4
Common stock shares converted														$ 4,000,000
Four Accredited Investors [Member]
Class of Stock [Line Items]
Additional shares issued									327,500
Sale of stock, price per share																								$ 8
Common stock shares converted									$ 2,620,000
Sales Executives [Member]
Class of Stock [Line Items]
Common stock shares converted																						$ 45,000
Common stock granted																						5,000
Share price																						$ 7
Stock based compensation																						$ 35,000
Shares vested																						90,000
Sales Executive [Member]
Class of Stock [Line Items]
Stock based compensation																							$ 149,100
Consultants [Member] | Consultants Agreement [Member]
Class of Stock [Line Items]
Common stock granted																							100,000
Share price																							$ 12.28
Stock based compensation																							$ 614,000
Amortization of Debt Issuance Costs																						$ 1,228,000
Consultant [Member]
Class of Stock [Line Items]
Share price																			$ 19			$ 18.60
Stock issued for services, shares																						10,000
Stock issued																			$ 47,500			$ 185,400
Two Individuals [Member]
Class of Stock [Line Items]
Stock-based compensation expense																							92,700
Consultant 1 [Member]
Class of Stock [Line Items]
Stock-based compensation expense																							$ 11,875
Series C Non Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized																						100
Preferred stock, par value																						$ 0.001

WARRANTS (Details)

WARRANTS (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Number of Shares Outstanding beginning balance	2,149,000	47,500
Weighted-average Exercise Price Outstanding beginning balance	$ 4.52	$ 6.11
Remaining Contractual Term (years) Outstanding beginning balance	9 years 7 months 17 days	6 years 10 months 24 days
Aggregate Intrinsic Value Outstanding beginning balance	$ 2,440,110	$ 289,500
Number of Shares, Granted	737,656	2,101,500
Weighted-average Exercise Price, Granted	$ 3.57	$ 4.48
Remaining Contractual Term (years) Granted	5 years	10 years
Aggregate Intrinsic Value, Granted
Number of Shares, Exercised
Weighted-average Exercise Price, Exercised
Aggregate Intrinsic Value, Exercised
Number of Shares, Expired/Forfeited	(315,000)
Weighted-average Exercise Price, Expired/Forfeited	$ 6.62
Remaining Contractual Term (years) Expired/Forfeitedd	8 years 5 months 15 days
Aggregate Intrinsic Value, Expired/Forfeited
Number of Shares Outstanding ending balance	2,571,656	2,149,000
Weighted-average Exercise Price Outstanding ending balance	$ 3.99	$ 4.52
Remaining Contractual Term (years) Outstanding ending balance	7 years 6 months	9 years 7 months 17 days
Aggregate Intrinsic Value Outstanding ending balance		$ 2,440,110
Number of Shares Exercisable	1,959,365	1,940,242
Weighted-average Exercise Price Exercisable	$ 4.45	$ 4.37
Remaining Contractual Term (years) Exercisable	8 years 3 months 29 days	9 years 7 months 13 days
Aggregate Intrinsic Value Exercisable		$ 2,403,058

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)					1 Months Ended				12 Months Ended
	Jul. 12, 2023	Jun. 01, 2023	Mar. 06, 2023	Aug. 01, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 31, 2022	Jul. 21, 2022	Oct. 31, 2023	Oct. 31, 2022	Dec. 31, 2023	Jul. 11, 2022
Share based compensation expense									$ 3,208,776	$ 3,916,590
Interest rate												10%
Unamortized compensation costs											$ 4,881,000
4 Investors [Member]
Purchase price					$ 250,000
Aggregate purchase price					725,000
Principal amount					$ 250,000
Interest rate					8%
Common stock purchase warrants					7,813
Warrant Shares [Member]
Number of warrants purchased			50,000
Exercise Price			$ 12
Risk free interest rate			3.98%
Term			5 years
Expected stock volatility			169%
Expected dividend rate			0%
Grant date fair value of warrants issued			$ 113,000
Unpaid and accrued compensation forgiven			$ 113,000
Warrant [Member]
Purchase price									80,469
Warrant [Member] | 4 Investors [Member]
Common stock par value					$ 0.001
Exercise price					$ 20
Consulting Agreement [Member]
Share based compensation expense									126,000
Sinnreich [Member] | Consulting Agreement [Member]
Share based compensation expense									59,300	343,000
Third Party [Member] | Consulting Agreement [Member]
Share based compensation expense									35,146	25,104
Warrant [Member] | Consulting Agreement [Member]
Share based compensation expense									1,960,000	408,333
Warrant [Member] | Five Separate Consulting And Employment Agreements [Member]
Number of warrants purchased							205,750
Term							10 years
Expected stock volatility							143%
Expected dividend rate							0%
Grant date fair value of warrants issued							$ 1,122,075
Share based compensation expense									237,638	133,363
Warrant [Member] | Five Separate Consulting And Employment Agreements [Member] | Minimum [Member]
Exercise Price							$ 4.80
Risk free interest rate							2.60%
Warrant [Member] | Five Separate Consulting And Employment Agreements [Member] | Maximum [Member]
Exercise Price							$ 6
Risk free interest rate							3.05%
Warrant [Member] | Sinnreich [Member]
Number of warrants purchased								200,000
Exercise Price								$ 6.80
Risk free interest rate								2.91%
Term								10 years
Expected stock volatility								144%
Expected dividend rate								0%
Grant date fair value of warrants issued								$ 1,332,000
Share based compensation expense									$ 1,332,000
Warrant [Member] | Skycrest [Member] | Consulting Agreement [Member]
Number of warrants purchased								750,000
Exercise Price								$ 4
Risk free interest rate								2.91%
Term								10 years
Expected stock volatility								144%
Expected dividend rate								0%
Grant date fair value of warrants issued								$ 2,940,000
Warrant [Member] | Greyt [Member] | Consulting Agreement [Member]
Number of warrants purchased								750,000
Exercise Price								$ 4
Risk free interest rate								2.91%
Term								10 years
Expected stock volatility								144%
Expected dividend rate								0%
Grant date fair value of warrants issued								$ 2,940,000
Warrant [Member] | Ian Bothwell [Member]
Number of warrants purchased									150,000
Exercise Price									$ 4
Risk free interest rate									2.91%
Term									10 years
Expected stock volatility									144%
Expected dividend rate									0%
Grant date fair value of warrants issued									$ 588,000
Unpaid and accrued compensation forgiven									$ 455,478
Warrant [Member] | Dr George Shapiro [Member]
Number of warrants purchased									15,750
Exercise Price									$ 4
Risk free interest rate									2.91%
Term									10 years
Expected stock volatility									144%
Expected dividend rate									0%
Grant date fair value of warrants issued									$ 61,740
Unpaid and accrued compensation forgiven									77,760
Warrant [Member] | Five Non Executive Directors [Member] | Directors Service Agreement [Member]
Number of warrants purchased						5,000
Exercise Price						$ 8.80
Risk free interest rate						3.69%
Term						10 years
Expected stock volatility						143%
Expected dividend rate						0%
Grant date fair value of warrants issued						$ 43,200
Share based compensation expense									160,373	23,079
Warrant [Member] | Third Party [Member] | Consulting Agreement [Member]
Number of warrants purchased				5,000
Exercise Price				$ 6.60
Risk free interest rate				2.60%
Term				10 years
Expected stock volatility				143%
Expected dividend rate				0%
Grant date fair value of warrants issued				$ 32,700
Share based compensation expense									24,525	$ 8,175
Warrant [Member] | Dr. Leider [Member] | Employment Agreement [Member]
Number of warrants purchased		285,000
Exercise Price		$ 2.40
Risk free interest rate		3.70%
Term		5 years
Expected stock volatility		168%
Expected dividend rate		0%
Grant date fair value of warrants issued		$ 684,000
Share based compensation expense									95,000
Warrant [Member] | Dr. Golub [Member] | Employment Agreement [Member]
Number of warrants purchased		250,000
Exercise Price		$ 2.40
Risk free interest rate		3.70%
Term		5 years
Expected stock volatility		168%
Expected dividend rate		0%
Grant date fair value of warrants issued		$ 600,000
Share based compensation expense									250,000
Warrant [Member] | Ms. Swartz [Member] | Employment Agreement [Member]
Number of warrants purchased	130,000
Exercise Price	$ 2.28
Risk free interest rate	4.10%
Term	5 years
Expected stock volatility	167%
Expected dividend rate	0%
Grant date fair value of warrants issued	$ 296,400
Share based compensation expense									$ 28,817

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

1 Months Ended

12 Months Ended

Jun. 06, 2023

Feb. 09, 2023

Nov. 22, 2022

Aug. 19, 2022

Jul. 21, 2022

Apr. 30, 2022

Mar. 29, 2021

Oct. 31, 2023

Nov. 30, 2023

Sep. 30, 2023

Aug. 16, 2023

Jul. 31, 2023

Jul. 19, 2023

Dec. 15, 2022

Nov. 30, 2022

Oct. 31, 2022

Sep. 30, 2022

Dec. 27, 2021

Nov. 30, 2021

Apr. 30, 2018

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 180,000

Due from related parties

$ 0

$ 128,939

Vested shares

7,233

Vested salary shares

40,767

Price per share

$ 10

Contract research organization outstanding

587,800

$ 244,900

Lawsuit settlement by cash

$ 45,000

$ 45,000

Lawsuit settlement by issuance of restricted common stock

10,000

2,000,000

Ian Bothwell [Member] | Warrant [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Unpaid and accrued compensation forgiven

$ 455,478

Number of warrants purchased

150,000

Exercise Price

$ 4

Mr. Bothwell’s [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Due from related parties

$ 0

Mr. Mitrani [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Due from related parties

75,900

Sinnreich [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Base salary

$ 25,000

Number of restricted shares issued

50,000

Amount paid to company

$ 50,000

Shares returned to the company

170,000

Vested warrants to purchase

200,000

Total shares return to company

170,000

Sinnreich [Member] | Warrant [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of warrants purchased

200,000

Exercise Price

$ 6.80

Dr. Leiders [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Base salary

$ 325,000

Shares to be purchased

285,000

Price per share

$ 2.40

Dr. Golub’s [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Base salary

$ 150,000

Shares to be purchased

250,000

Price per share

$ 2.40

Ms. Swartzs [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Base salary

$ 215,000

Price per share

$ 2.40

Common stock to purchase

$ 130,000

Skincare Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Minimum Purchase amount

$ 167,000

Amended Skincare Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Initial Purchase Order

$ 648,000

$ 403,200

Sales Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Initial Purchase Order

$ 403,200

Sales Agreement [Member] | Formulator [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Initial Purchase Order

$ 235,200

Executive Employment Agreements [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 300,000

Executive Employment Agreements [Member] | Albert Mitrani [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 150,000

Base salary

$ 300,000

Unpaid and accrued compensation forgiven

430,200

Executive Employment Agreements [Member] | Dr. Mari Mitrani [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 150,000

Base salary

300,000

Unpaid and accrued compensation forgiven

$ 563,455

Executive Employment Agreements [Member] | Ian Bothwell [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Annual salary

$ 200,000

$ 150,000

Base salary

$ 300,000

Reimbursed expenses

$ 44,600

Executive Employment Agreements [Member] | Mr. Mitrani [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Reimbursed expenses

$ 84,300

Consultant Agreements [Member] | Assure Immune [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Consultant agreements,description

Company and Consultant agreed to an amendment to the consulting agreement whereby the Consultant was issued 25,000 shares of common stock of the Company and received a $20,000 cash payment in exchange for satisfaction of approximately $200,000 in outstanding consulting fees due to the Consultant up through August 31, 2022. The parties also agreed to the reduction of future fees payable to the Consultant from $40,000 per month to $15,000 per month for the period September 2022 through March 2023. The Agreement was not renewed upon its expiration.

Under the terms of the Amendment, the Consultant received an additional 100,000 shares of common stock that vested 50% upon execution of the Amendment and the remaining 50% on December 31, 2021.

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative) - Integer	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Segment Reporting [Abstract]
Number of operating segments	1	1